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Abstract 
 
The public health burden of methicillin-resistant Staphylococcus aureus (MRSA) 
strains and the emergence of vancomycin resistance in S. aureus call for alternative strategies 
in chemotherapy. The FemXAB family of proteins is responsible for the assembly of the 
characteristic pentaglycine cross-bridge in the peptidoglycan of S. aureus, which is essential 
both for cell viability and for the expression of high level methicillin resistance. Fem proteins 
are, therefore, good candidate targets for the development of pathogen specific antimicrobial 
compounds, acting alone or synergistically with β-lactams. In this work, we characterized the 
localization of the FemX, FemA and FemB proteins (which add the 1st; 2nd and 3rd; 4th and 5th 
glycines of the crossbridge, respectively) during the bacterial cell cycle, using fluorescence 
microscopy. These proteins localized preferably at the membrane, including the septum, and 
de-localized in the absence of the peptidoglycan precursor. FemA and FemB proteins co-
localized in all cells observed during the different stages of the cell cycle, whilst FemX and 
FemA proteins co-localized in 64% of the cells. To determine if the FemB protein was 
dependent on FemA for proper localization, different approaches were used to attempt 
inactivation of the femA gene, but all were unsuccessful, suggesting that femA may be a lethal 
target. 
  
  
Sumário 
 
 Estirpes da bactéria Staphylococcus aureus que são resistentes à meticilina (MRSA) 
têm um profundo impacto na saúde pública. O aparecimento de estirpes resistentes à 
vancomicina, antibiótico de recurso para o tratamento de infecções por MRSA, urge o 
desenvolvimento de estratégias alternativas de quimioterapia. A família de proteínas 
FemXAB é responsável pela síntese da ponte lateral de pentaglicinas, característica do 
peptidoglicano de S. aureus, que é essencial tanto para a viabilidade da bactéria, como para a 
expressão de resistência elevada à meticilina. As proteínas Fem são alvos promissores para o 
desenvolvimento de compostos antimicrobianos específicos, que poderão actuar sozinhos ou 
em sinergia com o tratamento convencional. Neste trabalho, caracterizámos a localização das 
proteínas FemX, FemA e FemB (que adicionam a 1ª, 2ª e 3ª, 4ª e 5ª glicinas, respectivamente) 
durante o ciclo celular de S. aureus, por meio de microscopia de fluorescência. Demonstrou-
se que estas proteínas localizam-se preferencialmente na membrana bacteriana, incluindo o 
septo, e que deslocalizam-se na ausência do muropéptido percursor do peptidoglicano. As 
proteínas FemA e FemB co-localizaram durante o ciclo celular em todas as células 
observadas, enquanto que FemX e FemA co-localizaram em 64% das células observadas. 
Para determinar se a localização de FemB é dependente de FemA, foram utilizadas diversas 
estratégias que promovessem a inactivação de femA, porém nenhuma teve sucesso. Estes 
resultados permitem levantar a hipótese que FemA é uma proteína essencial para a célula.    
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Introduction 
 
Methicillin resistant Staphylococcus aureus 
 
Staphylococcus aureus is a Gram-positive coccus that is usually part of the human 
flora, mostly inhabiting the skin and the nasopharynx. However, it can also cause a wide 
range of infections, from skin and soft tissue infections to pneumonia, septicemia, infective 
endocarditis and osteomyelitis (Wenzel and Perl, 1995). Asymptomatic nasal carriers account 
for one third of the population (Gorwitz et al., 2008; Kluytmans et al., 1997) and are believed 
to be an important source of the strains that spread among individuals (Casewell and Hill, 
1986; Noble et al., 1967). S. aureus is transmitted usually by skin-to-skin contact between 
individuals or by contact with contaminated objects or surfaces (Kazakova et al., 2005; Lowy, 
1998; Miller and Diep, 2008; Muto et al., 2003). 
 Penicillin, a β-lactam antibiotic discovered accidentally in a mouldy S. aureus culture 
by Alexander Fleming in 1929, was one of the first antibiotics developed and its applicability 
in treating Gram-positive bacterial infections was deemed miraculous. However, a few years 
after the beginning of widespread use of penicillin in clinical practice, resistant strains were 
encountered in hospitals (Barber and Rozwadowska-Dowzenko, 1948). The situation has 
since escalated and, despite the development of successive generations of new antibiotics, 
infection by antibiotic-resistant strains of S. aureus has reached epidemic proportions globally 
(Chambers and Deleo, 2009; Grundmann et al., 2006). Particularly, methicillin-resistant S. 
aureus (MRSA) strains have become serious pathogens. Nowadays, MRSA represents >60% 
of nosocomial S. aureus isolates in many countries (Klevens MR, 2007) and carriage of 
hospital-acquired MRSA (HA-MRSA) is now endemic among hospitalized patients in many 
countries (Boyce et al., 1994), with reported proportions of MRSA in staphylococcal 
bloodstream infections as high as 44% in the UK (European Antimicrobial Resistance 
Surveillance System in http://www.rivm.nl/earss) and 50% in the US (National Nosocomial 
Infections Surveillance System in http://www.cdc.gov_ncidod_). Community-associated 
MRSA (CA-MRSA) emerged worldwide, having been reported in the US, Canada, Asia, 
South America and Europe (Laupland et al., 2008; Li et al., 2009; Moran et al., 2006; 
Vandenesch et al., 2003). CA-MRSA is now a major public health concern in the United 
States, where the vast majority of infections are caused by a clone known as pulsed-field type 
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USA300, responsible for particularly rapidly progressing fatal diseases and known for easy 
spreadability. Unlike HA-MRSA, CA-MRSA strains infect healthy individuals without 
predisposing risk factors and outside the hospital setting (Chambers, 2005; Kennedy et al., 
2008; Moran et al., 2006). 
Methicillin resistance has a broad spectrum, covering the entire β-lactam class of 
antibiotics, including penicillins, cephalosporins and carbapenems. Of particular note is the 
strain COL which was isolated from a patient in Colindale, UK, in 1961 and became probably 
the most studied MRSA strain (Jevons et al., 1963). MRSA strains used to be reliably 
susceptible to the glycopeptide vancomycin, which is usually only employed as a last resort 
drug; however, the ever increasing spread of MRSA infections in hospital settings prompted a 
significant increase in its use. This intensive selective pressure resulted in the emergence of 
vancomycin-intermediate (VISA) (Hiramatsu et al., 1997) and vancomycin resistant (VRSA) 
(CDC, 2002) S. aureus strains, further confirming the extraordinary ability of this bacterium 
to adapt and develop resistance. As of now, there have been reports of S. aureus isolates 
resistant to the most recent antibiotics introduced in clinal practice for the treatment of 
staphylococcal infections, namely potent protein synthesis inhibitors such as minocycline and 
linezolid (Bishburg and Bishburg, 2009) or the membrane depolarization effect of daptomycin 
(Gales et al., 2006; Hirschwerk et al., 2006; Howden et al., 2004; Llarrull et al., 2009). The 
development of compounds that do not inhibit bacterial growth on their own but either act 
synergistically with a primary antibiotic, by impairing expression of resistance, or decrease 
the virulence of bacterial cells, facilitating their elimination by the host immune system, 
seems to be an attractive alternative. 
 
Genetic mechanisms underlying bacterial resistance to β-lactams 
 
β-lactam antibiotics target penicillin binding proteins (PBPs), a family of proteins 
involved in bacterial cell wall biosynthesis. The first wave of resistant strains that emerged in 
the 1940s produced a plasmid-encoded β-lactamase (penicillinase) (Barber and 
Rozwadowska-Dowzenko, 1948; Kirby, 1944), which prompted the development of 
methicillin in 1959. Methicillin is a penicillin derivative that can still bind PBPs but is 
insensitive to β-lactamases. Unlike the first penicillin resistant strains, the major determinant 
of high-level β-lactam resistance in MRSA is  the mecA gene (Ubukata et al., 1989), which is 
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carried by an exogenous DNA element designated SCCmec (staphylococcal cassette 
chromosome mec) inserted in the chromosome of S. aureus. SCCmec integrates at a locus 
known as attBscc near the origin of replication (Holden et al., 2004; Katayama et al., 2003; 
Kuroda et al., 2001; Luong et al., 2002), a region that appears to be a common insertion point 
for acquired, foreign, DNA (Mongkolrattanothai et al., 2004; Noto et al., 2008). Integration 
and excision of the SCCmec mobile element is, in part, mediated by recombinases of the 
invertase/resolvase family, encoded by the included ccr gene complex. SCCmec seems to be a 
staphylococcal site-specific genomic island that serves as a vehicle of transfer for various 
genetic markers between staphylococcal species (Ito et al., 2001), as suggested by the 
existence of a structurally similar genetic element lacking mecA present in the chromosome of 
Staphylococcus hominis strain GIFU12263 (Katayama et al., 2003). mecA is a highly 
conserved gene among MRSA isolates (Oliveira et al., 2000) and it is proposed to have been 
originated from Staphylococcus sciuri (Wu et al., 2001) due to the finding of a mecA putative 
evolutionary ancestor in all isolates of this species. It seems unlikely though, that S. aureus 
acquired mecA directly from S. sciuri, as the two sequences lack the necessary identity level 
(Couto et al., 2003). mecA encodes for a 76 kDa penicillin-binding protein, PBP2a (also 
referred to as PBP2’), which was found in MRSA but not MSSA strains. PBP2a has lower 
affinity for β-lactam antibiotics than the other four PBPs native to S. aureus, and thus 
maintains its activity at therapeutic levels of methicillin, allowing the survival and growth of 
the bacteria (Hartman and Tomasz, 1984). Adjacent to mecA in the staphylococcal 
chromosome are mecR1, that encodes a membrane bound signal transdution protein, and 
mecI, encoding a tight transcriptional regulator (Sharma et al., 1998). The transcription of 
mecA can also be regulated by the plasmid-encoded bla system and it has been shown that the 
bla regulator is more effective at inducing mecA than the mec regulator. Most β-lactam 
antibiotics do not efficiently activate mecR1, explaining the occurrence of mecA positive pre-
MRSA isolates that are methicillin sensitive (Kobayashi et al., 1998). Again, selective 
pressure through antibiotic usage has resulted in isolates that either contain both regulation 
systems, in which β-lactam induced upregulation of mecA by the bla system allows for the 
transcription of PBP2a, or that display mutations/deletions in the mecI or mecA promoter 
region, with the same effect (McKinney et al., 2001).  
Blanket high level β-lactam resistance is, by no means, a simple matter of whether the 
strain carries the mecA gene or not. Additional native genes of S. aureus, also present in 
MSSA strains, were identified as essential for the full expression of methicillin resistance. By 
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constructing a large library of Tn551 insertional mutants in COL, it was possible to isolate 
mutants where the high and homogeneous level of methicillin resistance was reduced, 
although an intact mecA gene was still present (Berger-Bächi, 1983; de Lencastre and 
Tomasz, 1994). Each of these determinants was termed fem (factor essential for methicillin 
resistance) or aux (auxiliary) gene and approximately 30 fem genes have been identified (De 
Lencastre et al., 1999). Even if a strain carries mecA, the inactivation of fem genes usually 
leads to a heterogeneous profile of oxacillin resistance and lower minimum inhibitory 
concentrations of this antibiotic, despite the fact that the fem gene in question may not be 
essential for bacterial viability. Most of these factors are housekeeping genes that are 
probably present in all S. aureus strains and cover a wide array of functions, encoding 
proteins that have a direct or indirect role in peptidoglycan biosynthesis and turnover (ex. 
PBP2, FemA, MurF), proteins with putative sensory/regulatory activities (kinases or ABC 
transporters), alternate transcription factors (SigB) and proteins of unknown function (Berger-
Bächi and Rohrer, 2002; Berger-Bächi et al., 1992; De Lencastre et al., 1999). Although the 
exact relatedness of most of the fem factors to oxacillin resistance is still unresolved, their 
identification led to formidable insights into the structure of bacterial peptidoglycan. 
 
Peptidoglycan synthesis 
 
The key structural component in bacteria is the cell wall, composing the outermost 
layer of the cell in Gram-positive bacteria (except in capsulated ones) or lying underneath the 
outer membrane of Gram-negative bacteria. Its stability and integrity are critical for cell 
viability, shape and stress bearing. The scaffold of the cell wall consists, in both Gram-
negative and Gram-positive bacteria, of the cross-linked polymer peptidoglycan (PG), a mesh-
like structure also called murein. In Gram-positives this structure can be 20-40 nm thick 
(Vollmer et al., 2008). The cell wall envelope in S. aureus, as in most Gram-positive bacteria, 
is also comprised of polysaccharides, teichoic acids and proteins that are covalently or non-
covalently immobilized to the PG (Navarre and Schneewind, 1999). The cell is constantly 
under high internal osmotic pressure that is sustained by the long linear glycan strands of 
peptidoglycan, linked to each other via flexible peptide bridges. This bonding is referred to as 
crosslinking, and generates a strong but elastic structure that prevents the protoplast from 
lysing. The crosslinking organizes linear peptidoglycan strands into a single, large molecule, 
referred to as the murein sacculus (Glauner et al., 1988).  
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All cell wall-containing Eubacteria share the same basic PG architecture, with the 
glycan strands being composed of alternating 1,4-linked N-acetylglucosamine (GlcNAc, 
NAG) and N-acetylmuramic acid (MurNAc, NAM) disaccharide subunits. Attached to the 
carboxyl group of each MurNAc residue is a peptide chain commonly referred to as stem 
peptide whose amino acid composition is of considerable variation between species (Schleifer 
and Kandler, 1972). Also variable is the size and composition of the bridge crosslinking two 
stem peptides. In S. aureus, the very high crosslinking degree (up to 90%) has been attributed 
to the presence of long flexible pentaglycine bridges, supposedly able to connect glycan 
strands from different PG layers (Lapidot and Irving, 1977, 1979). The spatial structure of 
peptidoglycan is one of the most important unsolved structural problems in biochemistry, 
because of its inherent complexity and lack of pure and discrete segments for analysis. NMR 
studies using synthetic fragments of NAG-NAM(pentapeptide)-NAG-NAM(pentapeptide) 
tetrasaccharide suggested that peptidoglycan would have a structural aspect of a right-handed 
helical saccharide conformation corresponding to three NAG-NAM pairs per turn of the helix 
(Meroueh et al., 2006). This representation is better accommodated in the “scaffold model” 
(also called the hedgehog model) of peptidoglycan growth, which states that glycan strands 
grow outward of the cytoplasmic membrane and orthogonal to it (Dmitriev et al., 2004; 
Dmitriev et al., 2003), as opposed to the classical parallel mode that depicts layers of 
peptidoglycan parallel to the membrane. Furthermore, it implies that each glycan strand can 
crosslink to a maximum of three neighboring strands and the resulting honeycomb-like 
structure, as seen in Figure 1, is able to accommodate both syntethic machinery proteins 
(shown by small arrow) and large membrane bound proteins (shown by large arrow), which is 
in agreement with the atomic force microscopy images depicting S. aureus’ dot-filled surface 
described by Touhami and colleagues (Touhami et al., 2004). However, the scaffold model 
has its shortcomings, mainly because the amount of PG in the cell may not be enough to cover 
its surface entirely, at least when this model is applied to Gram-negative bacteria as it was 
demonstrated for Escherichia coli (Vollmer and Höltje, 2004). The “scaffold model” is also 
not compatible with recent electroncryotomography studies on Gram-negative sacculi that 
revealed a single layer of glycan strands parallel to the bacterial membrane (Gan et al., 2008). 
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Figure 1 – Top view of the structure of the polymeric peptidoglycan segment showing the glycan 
strands in orange and the stem peptides in green, in agreement with the “scaffold model”. Adapted 
from Meroueh et al., 2006. 
 
 
 Peptidoglycan synthesis in S. aureus can be divided in three stages (van Heijenoort, 
1998): it starts in the cytoplasm, where the reaction between nucleotide sugar-linked precursor 
UDP-N-acetylglucosamine (UDP-GlcNAc) and phosphoenolpyruvate, catalysed by MurA and 
MurB enzymes, is its first committed step (Rogers et al., 1980). The products of the reaction 
are inorganic phosphate and UDP-N-Acteylmuramic acid (UDP-MurNAc) (Eschenburg et al., 
2003; Skarzynski et al., 1996). Stem peptide synthesis begins at the carboxyl group of UDP-
MurNAc, with moieties L-Ala, D-Glu, L-Lys and D-Ala-D-Ala being sequentially added by 
MurC, MurD, Mur E and MurF enzymes, respectively, at the expense of ATP, thus 
originating the basic cytoplasmic precursor UDP-MurNAc-pentapeptide (Munoz et al., 1967; 
Tipper et al., 1967a; Tipper et al., 1967b). In the second stage (Figure 2), that takes place at 
the inner side of the membrane, the phospho-MurNAc-pentapeptide of the UDP-MurNAc-
pentapeptide is transferred to the membrane acceptor bactoprenol (also known as C55), 
yielding an intermediate known as lipid I. This reaction is catalyzed by the MraY translocase. 
Bactoprenol is a lipophillic molecule which allows the transport of hydrophilic molecules 
through the cell’s hydrophobic membrane (Ikeda et al., 1991). UDP-GlcNAc is then added by 
MurG to lipid I via a β-1,4 linkage, yielding lipid intermediate II (Mengin-Lecreulx et al., 
1991). The assembly of the amino acid bridge in S. aureus, for the subsequent crosslinking 
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reaction, is made by the FemXAB family of transferases, adding directly and sequentially five 
glycines to the L-Lys residue of the stem peptide on lipid II (Kopp et al., 1996). It is 
postulated that the lipid II intermediate is then translocated from the inner side to the outer 
side of the membrane via a translocase/flippase specific activity of a yet uncharacterized 
protein. A homologue of the MurJ (MviN) protein identified in E. coli (Ruiz, 2008) could be a 
likely candidate for this function. However, it was very recently demonstrated that deletion of 
four homologues of murJ in Bacillus subtillis caused no defects in bacterial growth, indicating 
that the corresponding proteins most likely do not function as flippases in this organism (Fay 
and Dworkin, 2009). 
 
 
Figure 2 – Membrane-bound stages of peptidoglycan biosynthesis in S. aureus. The formation of the 
pentaglycine interbridge, catalyzed by FemXAB proteins, precedes the translocation of the monomeric 
peptidoglycan unit across the cytoplasmic membrane, with subsequent polymerization via 
transglycosilation and transpeptidation reactions catalyzed by PBPs. UMP, uridine monophosphate; 
UDP, uridine diphosphate. Adapted from Schneider et al., 2004. 
 
 
The final stage of peptidoglycan synthesis consists in the incorporation of the new 
subunit (henceforth referred to as muropeptide) into the growing glycan chain and occurs 
mainly, if not only, at the bacteria’s division septum in S. aureus (Pinho and Errington, 2003). 
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This event is mediated by the membrane anchored PBPs, localized at the extracellular surface 
of the cytoplasmic membrane. PBPs can catalyze both a transglycosylase activity (TGase)– 
elongation of the glycan strands, and a transpeptidase activity (TPase) – peptide crosslinking 
between glycan strands. While all S. aureus native PBPs have a TPase domain, only PBP2 is 
bifunctional, capable of both transpeptidation and transglycosylation reactions (Goffin and 
Ghuysen, 2002; Massova and Mobashery, 1998; van Heijenoort 2001). In PBP2, the TGase 
and TPase domains are spatially well separated (Fuda et al., 2005). The transglycosilation 
reaction probably occurs between the reducing end of the MurNAc present in the nascent 
lipid-linked PG strand, and the C-4 carbon of the glucosamine residue in the lipid-linked 
precursor, thus attaching the new subunit to the growing glycan chain. Transpeptidation and 
crosslinking are accomplished by cleavage of the D-Ala-D-Ala bond at the terminus of one 
stem peptide in the glycan chain, which drives energetically the subsequent reaction between 
the peptidyl moiety and an acceptor present on the subunit being incorporated. In S. aureus, 
the acceptor is the last glycine of the synthesized bridge, whereas in bacteria with direct 
crosslinking, transpeptidation occurs between D-Ala and the dibasic amino acid of the stem 
peptide being incorporated (van Heijenoort, 1998). Cell growth and division require not only 
the synthesis of new PG but also its breakage, remodeling and reinsertion. This is 
accomplished by specific hydrolases that cleave PG bonds and can be classified as 
muramidases, glucosaminidases, amidases, endopeptidases and carboxypeptidases. It has been 
proposed that the role of hydrolases in processes of cell wall turnover, cell separation and 
muropeptide recycling is of critical importance (Höltje and Heidrich, 2001; Shockman et al., 
1996; Smith et al., 2000).  
The mechanism of inhibition of peptide crosslinking by β-lactams, which leads to cell 
death, is based on the irreversible acylation of the PBPs catalytic serine in the TPase active 
site by the antibiotic molecules, acting as suicide substrate homologues (Fuda et al., 2005; 
Waxman and Strominger, 1983). Acquired protein PBP2a is virtually non-susceptible to β-
lactam acylation but lacks a functional TGase domain. In MRSA strains that are challenged 
by a β-lactam, PBP2a’s TPase domain and PBP2’s TGase domain cooperate in building the 
staphylococcal cell wall, perhaps by means of a multi-enzymatic complex (Pinho et al., 2001). 
As PBP2 seems to be dependent on its transpeptidation substrates to localize to the division 
septum where PG is being synthesized, PBP2a could recognize the substrate, localize to the 
septum and recruit acylated PBP2 by direct or indirect protein interaction (Pinho and 
Errington, 2005). Glycopeptide antibiotics, of which vancomycin is an example, inhibit PG 
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biosynthesis by forming a non-covalent but stable complex with D-Ala-D-Ala residues at the 
terminus of the stem peptides, thus blocking the access of PBPs to their substrates (Pootoolal 
et al., 2002). 
 
Fem family of proteins 
 
Two closely linked fem factors, required for the full expression of methicillin 
resistance, that were identified after Tn551 insertions in the COL genome were termed femA 
and femB. femA and femB were mapped in an operon in the chromosome of MSSA strain 
NCTC 8325 and their inactivation in MRSA backgrounds was shown to have no effect on the 
production of PBP2a, therefore suggesting a direct role in cell wall synthesis (Berger-Bächi et 
al., 1992). These genes encode for the proteins FemA and FemB, which were the first 
described members of the class of non-ribosomal peptidyl transferases (Berger-Bächi et al., 
1989). These proteins are responsible for the assembly of the characteristic pentaglycine side-
chain that connects muropeptide subunits of peptidoglycan in S. aureus (Berger-Bächi and 
Tschierske, 1998; Kamiryo and Matsuhashi, 1972). It was found that FemA attaches only the 
second and third glycines of the peptide interbridge, whereas FemB adds exclusively the 
fourth and the fifth. Thus, it was also postulated that the addition of the first glycine would be 
catalyzed by a putative FemX protein (Figure 3) (Ehlert et al., 1997). Three femAB-like 
sequences were identified in the S. aureus genome: fmhA, fmhB and fmhC. Whereas 
inactivation of fmhA and fmhC sequences had no effect on growth and physiology, fmhB was 
shown to be an essential gene (Tschierske et al., 1999). fmhB was put under the control of a 
xylose regulon and a clear correlation between repression of the gene and accumulation of 
unsubstituted monomeric peptidoglycan precursors was observed. These results identified the 
protein encoded by the gene as FemX, the enzyme responsible for initiating the synthesis of 
the interchain peptide in the peptidoglycan. Precursor analysis of S. aureus cytoplasmic 
fractions revealed that only UDP-MurNAc-pentapeptide with no glycine substitutions was 
present, leading to the conclusion that FemX’s substrate would be either membrane bound 
lipid intermediate I or lipid intermediate II (Rohrer et al., 1999). The FemXAB family of 
proteins adds glycine residues directly as glycyl-tRNAgly (Matsuhashi et al., 1976). There are 
three different cell wall specific and two proteinogenic glycil-tRNAs in S. aureus, which 
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points to the hypothesis that each Fem factor may use dedicated gly-tRNAs (Kopp et al., 
1996). 
 
 
 
 
Figure 3– Pentaglycine side-chain formation of PG muropeptides in S. aureus. Glycines are added in 
a sequential fashion to L-Lysine, the third amino acid in the stem peptide. Each Fem protein has 
substrate specificity: FemX adds the first glycine; FemA adds the second and the third; FemB adds the 
fourth and fifth glycines. M, N-acetyl-muramic acid; G, N-acetyl-glucosamine. Adapted from Rohrer 
et al., 1999. 
 
 
The expression of femAB is regulated and was found to be increased in MRSA strains, 
relatively to MSSA strains, either by the binding of a putative protein to the upstream 
sequence, or by antibiotic induction (Li et al., 2008). Amino acid analysis of the 
peptidoglycan of S. aureus strains carrying a transposon inactivated femA locus showed a 
lower glycine to glutamic acid or lysine ratio, when compared to wild-type strains, decreased 
cell wall turnover and autolysis and also decreased susceptibilities to lysostaphin (Maidhof et 
al., 1991). Lysostaphin is a glycil-glycine endopeptidase, secreted by Staphylococcus 
simulans serovar Staphyloliticus, that preferably cuts between the third and fourth glycines of 
the crossbridge (Schneewind et al., 1995). The structural and physical effects of lysostaphin 
on the cell can be viewed in Figure 4. S. simulans protects itself from lysostaphin via a 
lysostaphin immunity factor (Lif), a FemAB-like protein that incorporates serines into the 
crossbridge (Tschierske et al., 1997).  
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Figure 4 – Time-lapse imaging by atomic force microscopy of a single S. aureus cell prior to and after 
incubation with 16 µg/ml lysostaphin. Major structural changes occur, including cell swelling, 
splitting of the septum (black arrows) and nanoscale perforations (white arrows). Adapted from 
Francius et al., 2008. 
 
 
Muropeptide analysis of femA mutants by HPLC techniques revealed an increase in 
the proportion of muropeptides with low crosslinking degree (monomers, dimers, trimers), 
relative to larger oligomers. Also, all pentaglycil substituted muropeptides were absent from 
the profile with concomitant accumulation of monomeric pentapeptides substituted with a 
single glycine residue and alternative muropeptides containing serine residues in the second 
position of the cross-bridge. Oligomers of single glycine substituted muropeptides may have 
been present in the muropeptide profile as well, although this was never verified. Overall, 
these conformational changes caused a reduction in the net degree of crosslinking by 10% in 
femA mutants. This data suggested a role for the femA gene product either in a cytoplasmic 
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phase of di-glycine biosynthesis or addition of glycine to the stem peptide at the inner 
membrane (de Jonge et al., 1993). Studies on femB inactivation revealed very similar 
consequences on peptidoglycan composition, with shortening of the peptide interbridges to 
three glycines. In both cases, pleiotropic consequences were observed as, besides altered cell 
wall composition, cells were shown to have aberrant septum formation and retarded cell 
separation, the so called femA-like phenotype (Figure 5). This led to the assumption that femB 
could be as important as femA, especially considering that femA and femB are transcribed in a 
polycistronic mRNA under the control of the same promoter (Henze et al., 1993).  
 
 
 
Figure 5 – Thin section of S. aureus femA mutant, displaying cells with irregular septa and 
defects in cell separation. Adapted from Henze et al., 1993. 
 
It is interesting to note that the Tn551 insertion on the femA gene occurred in the 
control region of the operon. This insertion led to a 90% decrease in femAB transcription, thus 
the femA inactivation mutant essentially behaved as a leaky femAB mutant. Insertional 
mutants of femB analyzed by Henze and colleagues (Henze et al., 1993), on the other hand, 
presumably led to complete knockout of the gene. These findings still raised the question of 
whether femA knockout mutations, which would abolish any residual transcription, would be 
incompatible with cell viability. Recent studies on the UK17 strain (which contains a 
nonsense mutation near the 3’ end of femA) peptidoglycan composition by solid-state NMR 
estimated a 57% reduction in the degree of crosslinking, relative to wild-type S. aureus. It was 
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postulated that, in order to achieve crosslinking with monoglycil bridges, a rearrangement of 
the whole cell wall structure seemed likely (Ling and Berger-Bächi, 1998; Sharif et al., 2009).  
 
FemA and FemB have 39% identity and 70% similarity to each other, however, FemB 
cannot substitute for FemA. It is unusual for two nearly identical proteins to have such high 
substrate specificities and it is likely that the active sites lie near the C-terminus of the 
proteins, as that is the region where FemA and FemB differ the most (Ehlert et al., 1997). 
femAB-like sequences have been identified not only in S. aureus but in other staphylococcal 
species as well (Alborn et al., 1996). Besides the aforementioned Lif factor in S. simulans, 
which was shown to complement a femB mutant (Tschierske et al., 1997), the epr gene in 
Staphylococcus capitis also catalyses the addition of serines into the crossbridge, protecting 
its producer from End, a lysostaphin-like glycil-glycine endopeptidase. Crossbridges 
containing serine in S. aureus have been shown to be incompatible with high methicillin 
resistance, contrary to pentaglycil ones, so it seems that either PBP2a has strict substrate 
requirements or that a putative interaction of this protein with Fem-like factors is altered in 
the presence of serine (Sugai et al., 1997). The low frequencies of serine and alanine 
containing crossbridges observed in all the FemA, FemB and FemAB mutants hint at residual 
activities of FemAB-like proteins, with specificities to amino acids other than glycines. It 
seems that during S. aureus’ evolution, cells that would synthesize pentaglycil bridges could 
crosslink glycan strands more efficiently and, therefore, bear the osmotic pressure inside 
better (Berger-Bächi and Tschierske, 1998). The event that triggered this leap was probably 
sequence duplication of a putative ancestral fem sequence (Berger-Bächi et al., 1989).  
 
Structural studies of Fem proteins 
 
Crystallography studies into the structure of S. aureus FemA provided priceless 
insights into the mechanism of this protein’s activity. FemA folds into a globular domain with 
two helical arms extending into the solvent (Figure 6) (Benson et al., 2002). Analysis of this 
globular domain revealed a three dimensional fold similar to the histone acetiltransferase 
(HAT) domain of Tetrahymena thermophila protein GCN5, which is known for its ability to 
bind peptide and peptide-like substrates. GCN5 is involved in acetylation of peptides in the 
core histones, by means of coenzyme-A (Dutnall et al., 1998). It was reasonable to assume, 
therefore, that FemA’s HAT domain could accommodate both the monoglycine substituted 
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stem peptide of lipid II and coenzyme A, the latter serving as an intermediate acceptor 
between the glycil-tRNA and the peptidoglycan precursor. Further data didn’t support the 
binding of coenzyme A to FemA, indicating direct transfer from the charged tRNA to the 
peptide. 
 
 
 
Figure 6 – Stereo view of the proposed structure of S. aureus FemA, depicting both the globular 
domain and the helical arms. White – deep L-shaped channel that can hold the stem peptide in an 
extended conformation; blue – antiparallel coiled-coil helical arms that could serve to hold an amino 
acid charged tRNA. Adapted from Benson et al., 2002. 
 
 
A deep L-shaped channel (Fig. 6 – in white) transversing FemA is a binding cavity 
suitable for an extended conformation of the stem peptide. The antiparallel coiled-coil helical 
arms (Fig. 6- in blue) could serve to hold an amino acid-charged tRNA molecule near the 
junction between the channel and the arms, during addition of the glycine residues to the 
growing peptide bridge (Benson et al., 2002) This type of mechanism has also been shown for 
the seryl-tRNA synthetase protein in Tetrahymena termophila (Biou et al., 1994; Cusack et 
al., 1996). After tRNA binding, structural changes would enable the enzyme to orient and 
position the acceptor end of the tRNA near the L-channel, for transfer of the glycine to the 
precursor. It was also postulated that addition of the two glycines would occur in a sequential 
fashion, with only one glycil-tRNA binding in the junction at a time. The substrate could 
probably be held in place between the two helixes located at the top of the channel. It can be 
argued that, after two rounds of transfer, the triglycil substituted stem peptide would not fit 
into the cavity anymore, preventing FemA from adding more glycines. An alternative 
mechanism states that the addition of the two glycines could be accomplished by two separate 
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FemA proteins interacting with each other near the substrate (Benson et al., 2002). Bacterial 
two hybrid studies showed homodimerization of FemA. Homodimerization was also found on 
FemB as well as heterodimerization between FemA and FemB, therefore it seems possible 
that both proteins function in a large complex attached to its substrate near the membrane. 
This data does not necessarily imply, however, that interaction contributes to the mechanism 
of glycine attachment. No interactions were found between FemX and the other Fem proteins 
nor between FemX monomers, suggesting that FemX is very likely a monomer in vivo, 
although physical interactions mediated by an auxiliary molecule cannot be ruled out (Rohrer 
and Berger-Bächi, 2003).  
 
In contrast to S. aureus, Gram-negative Weissella viridescens (basionym Lactobacillus 
viridescens) contains monoglycil substituted UDP-MurNAc-pentapeptide in the cytoplasm, 
suggesting that in these bacteria, FemX adds the glycine before the translocation to 
bactoprenol occurs (Hegde and Shrader, 2001). Structural analysis of the FemX protein from 
Weissella viridescens (hereafter referred to as FemXwv) provided new insights into FemXAB 
protein family folding. FemXwv, unlike S. aureus FemX, is active in the cytoplasm, 
recognizing UDP-MurNAc-pentapeptide as a substrate and adding an alanyne. This enzyme 
contains one domain for UDP-MurNAc-pentapeptide binding and one for alanyl-tRNA 
binding (Biarrotte-Sorin et al., 2004). The overall structure of FemXwv is similar to S. aureus 
FemA (Benson et al., 2002). However, the former lacks the coiled-coil arms described in the 
latter. This structural characteristic was proposed to divide the FemXAB family in two 
groups: group 1 proteins contain the helical arms and comprise FemA and most FemXAB-
related sequences, including those from staphylococci, enterococci and streptococci; group 2 
proteins lack the structural motif and, along with FemXwv, comprise Fem-like sequences from 
Streptomyces coelicolor, Deinococcus radiodurans, Treponema pallidum and Borrelia 
burgdorferi (Biarrotte-Sorin et al., 2004). Streptococcus pneumoniae Fem subgroup I protein 
MurM incorporates either alanines or serines to the growing peptide chain. This was shown to 
be a consequence of allelic variability in a 35 amino acid sequence contained in the coiled-
coil domain of the protein. This supports the notion that the species of aminoacyl-tRNA that 
is added to the peptide chain is dependent on specific interactions at the junction between the 
helical arms and the globular domain of Fem proteins (Filipe and Tomasz, 2000). FemXwv 
contains a cleft in domain I, similar to the one in FemA, that can accommodate the UDP-
MurNAc substrate, which was shown to make polar interactions with the protein. Structural 
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differences observed between the complexed and the non-complexed versions of FemXwv are 
minor, with noteworthy exceptions. For example, amino acid Lys36, equivalent to Lys33 of 
FemA, was reported to undergo a notable change in conformation, thus suggesting that it 
could be a critical residue for substrate binding. Domain II comprises a long channel with a 
global positive electrostatic surface potential that could complement the negatively charged 
phosphate backbone of tRNA. Interestingly, residue Tyr254 (equivalent to Tyr327 in FemA), 
strictly conserved across the FemXAB family, points inside the channel, presenting its side 
group to the entering tRNA. This orientation suggests a role in tRNA binding and recognition 
(Biarrotte-Sorin et al., 2004). Subsequent studies on FemXwv’s structure identified nine 
residues located in the binding cavity for UDP-MurNAc-pentapeptide as possible essential 
factors for protein activity, six of which are depicted in Figure 7 (Maillard et al., 2005). 
 
 
 
Figure 7 – Structure of the binding cavity of FemXwv superimposed with the UDP-MurNAc-
pentapetide substrate (in magenta). Secondary structure of the protein is colored in dark blue. The 
FemXwv side chains of relevant residues are colored in yellow/orange for the apo wild type enzyme 
and in cyan for the complex. Adapted from Maillard et al., 2005. 
 
Site-directed mutagenesis of these residues showed that two of them, Lys36 and 
Arg211, when substituted by methionines, decreased transferase activity below detectable 
levels without affecting protein folding. Furthermore, analogues of UDP-MurNAc-
pentapeptide lacking the phosphate groups or the C-terminal D-Ala-D-Ala residues were not 
substrates of FemXwv. It seems that Lys36 and Arg211 participate in a complex hydrogen 
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bond network that connects the C-terminal D-Ala residues to the phosphate groups of UDP-
MurNAc-pentapeptide and constrains the substrate in a conformation essential for transferase 
activity. By analogy, the corresponding residues Lys33 and Arg220 in S. aureus FemA should 
also be critical for the enzyme’s function, albeit in this case, the phosphate groups recognized 
in the lipid II are linked to bactoprenol (Maillard et al., 2005).  
 
Biochemical studies of the Fem proteins in vitro activity 
 
In vitro reconstitution of the inner-membrane bound steps of peptidoglycan synthesis, 
leading to the production of the lipid II-Gly5 precursor was achieved from purified lipid I, 
lipid II, FemXAB proteins and glycil-tRNA synthetase. Lipid II was identified as the only 
substrate of the S. aureus peptidyltransferases and it was shown that these proteins were 
active individually and were highly substrate specific. As neither the soluble UDP-MurNAc-
pentapetide nor lipid I were converted to glycine-labeled precursors, it is assumed that FemX 
protein and, by analogy, FemA and FemB, should recognize lipid II via the sugar moiety 
MurNAc-GlcNAc, which is in agreement with the aforementioned placement of the substrate 
in the L-shaped groove. Interestingly, when lipid II was incubated with FemXA, only lipid II-
Gly3 was found. A scenario where both FemA and FemB function as homodimers, in a way 
that each subunit is loaded with a Gly-tRNA to ensure sequential addition of both Gly to the 
growing interpeptide bridge seems likely. It is reasonable to assume that this is a tightly 
coordinated process interlinked with the other membrane associated steps of cell wall 
synthesis. Moreover, it is possible that Fem proteins are transiently associated with each 
other, as well as with other cell wall biosynthesis enzymes (Schneider et al., 2004). 
 
In this thesis, our goal was to characterize the localization of the FemXAB family of 
proteins in live S. aureus cells, during the cell cycle and in the presence or absence of 
different antibiotics, by means of fluorescence microscopy techniques.  
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Materials and Methods 
 
Bacterial strains and plasmids 
 
 
 The bacterial strains and plasmids used in this study are described in Table 1. 
 
 
Table 1- Strains and plasmids used in this work. 
Strain/Plasmid Genotype/Description Origin/Reference 
Strain   
S. aureus RN4220 MSSA strain, restriction negative Rockefeller University 
collection 
S. aureus UK17 mecA+, femA- (Ehlert et al., 1997) 
S. aureus COL Homogeneous MRSA (MIC 800 ug/ml) Rockefeller University 
collection 
E.coli DH5α Cloning strain, recA endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
ϕ80 ∆lacZ∆M15 
Gibco-BRL 
RNpFemX-N RN4220 expressing FemX with an N-terminal GFP fusion, Ermr This work 
RNpFemX-C RN4220 expressing FemX with a C-terminal GFP fusion, Ermr This work 
RNFemA-C RN4220 expressing FemA with a C-terminal mCherry fusion This work 
RNpFemB-C RN4220 expressing FemB with a C-terminal GFP fusion, Ermr This work 
RN-FemXA RN4220 expressing FemX with an N-terminal GFP fusion and 
FemA with a C-terminal mCherry, Ermr 
This work 
RN-FemAB RN4220 expressing FemB with a C-terminal GFP fusion and 
FemA with a C-terminal mCherry fusion, Ermr 
This work 
COLpFemX-N COL expressing FemX with an N-terminal GFP fusion, Ermr This work 
COLpFemX-C COL expressing FemX with a C-terminal GFP fusion, Ermr This work 
COLFemA-C COL expressing FemA with a C-terminal mCherry fusion This work 
COLpFemB-C COL expressing FemB with a C-terminal GFP fusion, Ermr This work 
COL-FemXA COL expressing  FemX with an N-terminal GFP fusion and FemA 
with a C-terminal mCherry fusion, Ermr 
This work 
COL-FemAB COL expressing FemB with a C-terminal GFP fusion and FemA 
with a C-terminal mCherry fusion, Ermr 
This work 
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 Table 1 (cont.)  
Strain/plasmid Genotype/description Origin/Reference 
   
COLpPBP2-31 COL expressing PBP2 with anN-terminal GFP fusion, Ermr (Pinho and Errington, 
2005) 
Plasmid   
pMAD E. coli-S. aureus shuttle vector with the bgaB gene encoding a ß-
galactosidase. Ampr/Ermr 
(Arnaud et al., 2004) 
pSG5082 Plasmid for C-terminal GFP fusions of proteins, Ampr/Ermr (Pinho and Errington, 
2004) 
pSG5086 Plasmid for N-terminal GFP fusions of proteins, Ampr/Ermr (Pinho and Errington, 
2005) 
pBCB4-CHERRY Plasmid for C-terminal mCherry fusions of proteins,  
Ampr/Ermr 
P. Pereira 
(unpublished) 
pFemA-C Derivative of pMAD containing femA-mCherry-femB This work 
pFemB-C Derivative of pSG5082 containing  femB upstream of gfpmut M. Santos 
(unpublished) 
pFemX-C Derivative of pSG5082 containing  femX upstream of gfpmut M. Santos 
(unpublished) 
pFemX-N Derivative of pSG5086 containing femX downstream of gfpmut This work 
pFemA-UK Derivative of pMAD containing a femA with a nonsense mutation This work 
pFemA-Lys33 Derivative of pFemA-C containing a femA with a K33A 
substitution 
This work 
pFemA-Arg220 Derivative of pFemA-C containing a femA with an R220A 
substitution 
This work 
pFemA-Tyr327 Derivative of pFemA-C containing a femA with a Y327Ala 
substitution 
This work 
   
 
 
 S. aureus strains were grown on tryptic soy broth (TSB, Difco), supplemented with 
erythromycin at 10 µg/ml, when needed, with aeration at 37°C, except where indicated. E. 
coli strains were grown in Luria–Bertani broth (Difco), supplemented with ampicillin at 100 
µg/ml when needed, with aeration at 37°C. Growth was followed by monitoring the optical 
density at 600 nm. 
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Molecular cloning methods 
 
The oligonucleotide primers used in this study are described in Table 2, restriction 
sequences are underlined. 
 
 
 
Table 2 – Oligonucleotide primers used in this study 
 
Primer Name Nucleotide Sequence (5’ – 3’) 
  FEMAKP1 TTGGCCACTATGAGTTAGCGCTTGCTGAAGGTTATG 
FEMAKP2 CATAACCTTCAGCAAGCGCTAACTCATAGTGGCCAAC 
FEMAKP3 TTGGCCACTATGAGTTAG 
FEMAP1eco CCGGGAATTCGCAAATACGGAAATGAAATTAATTAACGAG 
FEMAP2 AGAACCAGCAGCGGAGCCAGCCGACTTAAAAATTCTGTCTTTAAC 
FEMAP3 TCCGCTGCTGGTTCTGGCGAGTTCATGATTGTGAGCAAGG 
FEMAP4 TTTGATAATTCCCTTCCTAGTACAGCTCGTCCATGCCACC 
FEMAP5 AAGGGAATTATCAAAACATGAAATTTACAGAGTTAACTGTTACCG 
FEMAP6bam GGCGCGCGGGATCCCTATTTCTTTAATTTTTTACGTAATTTATC 
FEMARP1 AAAAGCTTTTGCTGATGCCGATGACAAAGCCTACTAC 
FEMARP2 TAGTAGGCTTTGTCATCGGCATCAGCAAAAGCTTTTG 
FEMARP3 CAAAAGCTTTTGCTGATG 
FEMAUP1bam GCTGCGGATCCGAGTTTGGTGCCTTTACAGATAG 
FEMAUP2eco GCAGCGAATTCGGCTCGATGTATCATACTC 
FEMAUP3 ACAACTTGATGCAAATGAGT 
FEMAUP4 GCTCGATGTATCATACTC 
FEMAuutr CTATAAAAGTATACGCAATTAAAGCG 
FEMAYP1 CAATCCATTTGAAGTTGTTGCCTATGCTGGTGGTACATC 
FEMAYP2 GATGTACCACCAGCATAGGCAACAACTTCAAATGGATTG 
FEMAYP3 ATCCATTTGAAGTTGTTG 
FEMBP1kpn GTTGGTACCGATTCCTTGAACGTGATGAG 
FEMBP2xho CCGTCTCGAGTTTCTTTAATTTTTTACGTAATTTATCC 
FEMXP1kpn GCAGGTACCTTCTTAACGCGTGATATTAG 
FEMXP2xho CCGACTCGAGTTTTCGTTTTAATTTACGAG 
FEMXP3xho AAAGGGCTCGAGATGGAAAAGATGCATATCAC 
FEMXP4eco CCCTTTGAATTCGATTTCAGTCGTTAATCTATTTTCG 
gfpmutP1 TTTGTATAGTTCATCCATGCCATGTGTAATCC 
gfpmutP2 AGTAAAGGAGAAGAACTTTTCACTGGAGTTGTC 
pMADII CGTCATCTACCTGCCTGGAC 
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DNA purification 
 
For chromosomal DNA purification, cell cultures were grown to exponential phase. A 
30 ml sample was collected at OD620nm of 1, pelleted and resuspended in 50mM EDTA. Cells 
were then incubated at 37ºC with 5µl of lysostaphin (10 mg/ml, Sigma) and 10µl of RNAse 
(10mg/ml, Sigma) for 30min and, subsequently, incubated at 80ºC with Nuclei lysis solution 
(Promega) for 5min. Protein precipitation solution (Promega) was added and cells were 
incubated 10min on ice. DNA was then precipitated with isopropanol, washed with ethanol 
70% and resuspended in sterile water.  
For the screening of S. aureus mutants by PCR, genomic DNA was isolated from 1-ml 
cultures grown overnight using a modified alkaline wash protocol (Hall et al., 2003). Briefly, 
cells were pelleted, resuspended in 500 µl of alkaline wash solution (0.05 M sodium citrate, 
0.5 M NaOH), and incubated at room temperature for 20 min. Tubes were spun at 14.000 x g 
for 1 min, pellets were washed with 500 µl of 0.5 M Tris-HCl, pH 8.0, and subsequently 
resuspended in 100 µl of sterile water. Tubes were placed in boiling water for 10 min and 
spun at 14.000 x g for 5 min. Five microliters of supernatant were used in each 50 µl PCR 
reaction.  
 Plasmid DNA from E. coli strain was extracted using Wizard SV Plus Miniprep kit 
(Promega). Ethanol precipitation was used for the concentration of DNA. Quantification of 
DNA was carried out by comparing the fluorescent intensities of the samples and DNA 
markers on 0.8% agarose gels stained with ethidium bromide 
 
DNA manipulations 
 
Restriction enzymes were purchased from New England Biolabs. DNA fragments 
were digested with restriction enzymes of interest (0.5-1µg DNA, 1X restriction buffer, and 
1X BSA if required, 20U restriction endonuclease and water to 50µl for 16 hours), purified 
using Wizard SV Plus Cleanup kit (Promega) and ligated together. A typical ligation reaction 
contains vector and insert DNAs (0.1–5 µg), 1X Ligase buffer, 20–100 U T4 DNA ligase 
(Fermentas) for 1h at room temperature or overnight at 4ºC. PCR reactions were done with 
either the GoTaq Polymerase (Promega) for colony screenings or Phusion polymerase 
(Finnzymes) for subsequent cloning into plasmids, both following manufacturer’s 
instructions, except where noted.  
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Transformation of E.coli 
 
Competent cells were prepared according to the Rubidium chloride method 
(Sambrook et al., 1989). Briefly, early exponential cells (O.D.600nm = 0.3-0.4) were 
incubated on ice for 15min, centrifuged and resuspended in 1/3 of culture volume of RF1 
buffer (RbCl 100mM; MnCl2 tetrahydrate 50mM; Potassium acetate pH 7,5 35mM; Calcium 
chloride bihydrate 10mM; Glycerol 15%). Cells were incubated on ice for 15 minutes and 
pelleted. The pellet was resuspended in 1/2 volume of RF2 buffer (MOPS 10mM; RbCl 
10mM; Calcium chloride bihydrate 75mM; Glycerol 15%) and stored at -80°C in 300 µl 
aliquots. For the transformation, either plasmid or ligation mixtures were added to the 
competent cells and kept on ice for 10 min. Foreign DNA was introduced using a heat shock 
method (45 sec at 40°C). Cells were mixed with 1 ml LB medium and incubated at 37°C for 
1h. Appropriate aliquots were spread on antibiotic selection plates.  
 
 
S. aureus transformation and transduction 
 
Transformation of S. aureus 
 
S. aureus competent cells were prepared essentially as previously described (Kraemer, 
1990). Briefly, bacteria were grown to O.D.600nm = 0.4 and centrifuged. Cells were washed 
once with equal culture volume of ice cold filter sterilized 0.5M sucrose (Sigma), and once 
with half the volume of 0.5M sucrose. Cells were then incubated on ice for 20min and 
resuspended in 1/100 of the initial volume of 0.5M sucrose with 10% glycerol (Fluka), and 
stored at -80°C. 45µl of competent cells were mixed with 5 - 8 µl DNA purified using the 
Wizard SV Plus clean-up kit (Promega) and electroporated. The standard electroporation 
conditions were: 2.5 kV, 100 Ω, 25 µF in a 0.2cm BioRad Gene Pulser cuvette. After 
electroporation, cells were mixed with 1 ml TSB and incubated for 1 h at 37°C. Appropriate 
dilutions were spread on antibiotic selection plates. 
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Transduction with phage 80α  
 
Transduction was done as previously described (Oshida and Tomasz, 1992). For the 
preparation of transduction lysates, donor strains were grown in Tryptic Soy Agar (TSA, 
Difco) overnight at 37ºC. Cells were collected with 1ml of TSB and calcium chloride was 
added to a final concentration of 5 mM. Phage 80α lysate was diluted (10-2, 10-3 and 10-4) in 
phage buffer (1mM MgSO4, 4mM CaCl2, 50mM Tris-HCl pH 7.8, 5,9g/l NaCl and 1g/l 
gelatin). The cell suspension (10µl) was mixed with 10µl of each of the phage dilutions and 
3ml of phage top agar (casamino acids 3g/l, Difco; yeast extract 3g/l, Difco; sodium chloride 
5,9g/l, Sigma; and agar 5g/l, Difco, pH 7.8), supplemented with 5mM of CaCl2, pre-warmed 
for one hour at 45ºC. The mixture was poured onto phage bottom agar (identical to the top but 
with 15g/l of agar) with 5mM of CaCl2 and incubated over night at 30ºC. On the following 
day, phage buffer (3ml) was added to plates showing confluent lysis. Plates were kept at 4ºC 
for one hour. The phage top agar and the phage buffer were then collected into a centrifuge 
tube and vigorously vortexed in order to disrupt the phage bottom agar. The tubes were kept 
for one hour inverted at 4ºC. The agar was centrifuged at 3500 rpm for 30min at 4ºC. The 
supernatant was collected and filtered through a 0.45 µm sterile filter. For the transduction, 
recipient strains were grown overnight in TSA at 37ºC. Cells were collected with 1ml TSB 
with CaCl2 5mM. Cell suspension (100µl) was added to the phage lysate (1µl and 10µl) and 
phage buffer was added to a final volume of 300µl. A control tube without phage lysate was 
also prepared. The mixtures were incubated for 20min at 37ºC and 3ml of 0.3GL top agar 
(casamino acids 3g/l, Difco; yeast extract 3g/l, Difco; NaCl, 5,9g/l Sigma; sodium lactate 60% 
syrup, 3,3ml/l, sigma; glycerol 50%, 2ml/l, Sigma; Tri-sodium citrate, 0,5g/l, Sigma; and agar 
7,5g/l, Difco; pH 7,8) at 45ºC (pre-warmed for one hour) were added. The mixture was then 
poured onto plates made with 10ml of 0.3GL bottom agar (identical to 0.3GL top but with 
15g/l agar) with 30mg/l of Erythromycin (Sigma) and 20ml of 0.3GL bottom agar without 
antibiotic. Plates were used within one hour after preparation. 
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Construction of derivatives of the FemXAB proteins 
 
Construction of FemX-GFP fusions 
 
A 650 bp fragment of the 3’ end of the femX gene was amplified from COL using 
primers FEMXP1kpn/FEMXP2xho, digested and cloned into Kpn/XhoI restriction sites of 
pSG5082, upstream and in frame with gfpmut resulting in pFemX-C. The entire femX gene 
was amplified from COL using primers FEMXP3xho/FEMXP4eco, digested and cloned into 
the XhoI/EcoRI restriction sites of pSG5086, downstream and in frame with gfpmut, resulting 
in pFemX-N. Both plasmids were electroporated into RN4220 competent cells and transduced 
to COL. Transformants were selected on Ery 10 µg/ml plates at 37ºC and successful 
integration of the plasmids into the chromosome was validated by PCR, with primer pairs 
FEMXP1kpn/GFPMUTP1 for the C-terminal fusion and GFPMUTP2/FEMXP4eco for the N-
terminal fusion. C-terminal GFP mutants of FemX were termed RNpFemX-C and 
COLpFemX-C. N-terminal GFP mutants of FemX were termed RNpFemX-N and 
COLpFemX-N 
 
Construction of a FemB-GFP fusion 
 
A 660 bp fragment of the 3’ end of the femB gene was amplified from COL using 
primers FEMBP1kpn and FEMBP2xho, digested and cloned into KpnI/XhoI restriction sites 
of pSG5082, upstream and in frame with gfpmut, resulting in pFemB-C. The plasmid was 
then electroporated into RN4220 competent cells and transduced to COL. Transformants were 
selected on Ery 10 µg/ml plates at 37ºC and successful integration of the plasmid into the 
chromosome was validated by PCR with primer pair FEMBP1kpn/GFPMUTP1. In this way, 
mutants RNpFemB-C and COLpFemB-C were obtained. 
 
Construction of FemA-mCherry fusions 
 
In order to introduce a femA-mcherry fusion into the chromosome of S. aureus without 
disrupting the femAB operon, the thermosensitive pMAD vector (Arnaud et al., 2004) was 
used to clone a femA-mcherry-femB PCR fragment (Figure 8). 
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Figure 8 – Strategy for the construction of the fusion femA-mcherry-femB. ML = protein linker. P1-
P6: primers FEMAP1eco, FEMAP2, FEMAP3, FEMAP4, FEMAP5 and FEMAP6bam, respectively. 
 
Construction of the fusion gene was made as previously described (Wurch et al., 
1998). In the first PCR, femA and femB genes were amplified from COL genomic DNA with 
primer pairs FEMAP1eco/FEMAP2 and FEMAP5/FEMAP6, respectively. mcherry was 
amplified from pBCB4-Cherry with primers FEMAP3 and FEMAP4. These PCRs were done 
using Phusion polymerase (Finnzymes) in 20 cycles of: denaturation at 98ºC for 10s, 
annealing at 74ºC for 20s, extension at 72ºC for 90s. Primer FEMAP2 contains a point 
mutation to remove the femA stop codon and primer FEMAP4 contains a point mutation to 
insert a stop codon at the end of mCherry, both depicted by an asterisk in Figure 8. Both 
primers FEMAP2 and FEMAP3 include an overlapping sequence of nucleotides encoding a 
peptide linker. In the annealing reaction, the overlapping sequences from primer pairs allowed 
the fusion of the construct. Equimolar amounts of each PCR product were mixed together and 
subjected to 1 cycle in the conditions described above. In the second PCR, primers 
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FEMAP1eco and FEMAP6bam were used to amplify the fusion gene with the Phusion 
polymerase for 20 cycles of: denaturation at 98ºC for 10s, annealing at 74ºC for 20s, 
extension at 72ºC for 4m. The final PCR fragment was cut with EcoRI and BamHI and cloned 
into pMAD vector, generating plasmid pFemA-C. After extraction of the plasmid from E. coli 
DH5α, restriction digest confirmation was performed with the same enzymes used for cloning 
and the plasmid insert was sequenced. pFemA-C was electroporated into RN4220 competent 
cells at 30ºC to keep the plasmid from integrating. Transformants were selected on an 
erythromycin 10 µg/ml plate. The plasmid was transduced from RN4220 background to COL 
and transductants were selected on erythromycin 10 µg/ml plates at 30ºC. 
 
Both for COL and RN4220, one erythromycin resistant colony was inoculated in fresh 
TSB containing Ery 10 µg/ml, at 30ºC for 16 hours. The overnight culture was diluted 1:1000 
to the same medium and incubated for 7 hours, then diluted 1:1000 again and incubated in the 
same medium at 43ºC overnight. The overnight culture was serially diluted to 10-4, 10-5 and 
10-6 and plated on TSA containing Ery 10 µg/ml and bromo-chloro-indolyl-galactopyranoside 
(X-GAL) 100 µg/ml and incubated overnight at 43ºC. Several light blue colonies were picked 
and restreaked in the same conditions. Genomic DNA of selected clones was purified and 
PCR was done to confirm integration (Figure 9 –step 2) using one primer complementary to 
the upstream region of femA (FEMAuutr) and an internal pMAD primer (PMADII). One 
positive clone for integration was inoculated in TSB medium with no antibiotic at 30ºC 
overnight. The overnight culture was diluted 1:500 into TSB, in the same conditions. After 7 
hours, the culture was serially diluted to 10-3, 10-4 and 10-5 and plated to TSA + X-Gal 100 
µg/ml at 43ºC overnight. White colonies, representing candidates for the double crossover 
event and loss of the plasmid (Figure 9, step 3), were restreaked on TSA. Colonies which 
retained the mcherry fusion to femA in the chromosome were first selected by susceptibility to 
erythromycin and then by PCR screening using PFEMAP1eco and PFEMAP2xho. These 
mutants were named COLFemA-C and RNFemA-C. 
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Figure 9 – Allelic replacement strategy using pMAD derived plasmid pFemA-C. Integration through 
femA is shown but homologous recombination in the first step can also occur through the femB region. 
In the third step, the second recombination event and loss of the plasmid can yield a wild type strain 
(A) or a strain containing a femA-mcherry fusion in the femA native locus (B). Step 1 – homologous 
recombination between pFemA-C and the bacterial chromosome; Step 2 – integration; Step 3 – 
excision and loss of the plasmid. 
 
Construction of strains encoding fluorescent derivatives of two Fem proteins  
 
In order to generate a strain expressing simultaneously FemA-mCherry and FemB-
GFP, plasmid pFemB-C was electroporated into RNFemA-C competent cells. Transformants 
were selected on Ery 10 µg/ml plates at 37ºC and named RN-FemAB. The fragment 
containing the femAB operon was transduced to COL, with selection on Ery 10 µg/ml plates at 
37ºC. The resulting strain was named COL-FemAB. The presence of both fusion genes was 
confirmed by PCR with primers PFEMAP1eco and GFPMUTP1. 
In order to generate a strain expressing simultaneously GFP-FemX and FemA-
mCherry, plasmid pFemX-N was transduced from RNpFemX-N into COLFemA-C. 
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Transductants were selected on Ery10 µg/ml plates at 37ºC and named COL-FemXA. 
Integration of the plasmid was confirmed with primers GFPMUTP2 and FEMXP4eco. 
 
Mutagenesis of the femA gene 
 
A 1900 bp DNA fragment encompassing femA was amplified from strain UK17 using 
primers FEMAUP1 and FEMAUP2. This strain contains a nonsense mutation at position 985 
of the femA gene. The PCR fragment was digested and cloned into the EcoRI/BamHI 
restriction sites of pMAD, generating plasmid pFemA-UK.  
In order to construct mCherry-tagged femA defective mutants, the following residue 
replacements were performed in the femA region of the pFemA-C plasmid: Lys33 to Ala 
(resulting in plasmid pFemA-K33), Arg220 to Ala (resulting in plasmid pFemA-R220) and 
Tyr327 to Ala (resulting in plasmid pFemA-Y327). Site-directed mutagenesis was done using 
primer pairs FEMAKP1/FEMAKP2, FEMARP1/FEMARP2, FEMAYP1/FEMAYP2 for the 
Lys, Arg and Tyr mutations, respectively. Primers of each pair are complementary to each 
other and contain the desired mutations in the middle, to replace residues K33, R220 and 
Y327 with alanines. PCR reactions were done with Phusion polymerase following 
manufacturer’s instructions but using a template/primer concentration ratio of 2. PCR 
products were incubated at 37ºC for 1 hour with DpnI restriction enzyme, to digest the 
methylated pFemA-C template. The amplicons were ligated and transformed to DH5α 
competent cells. Following plasmid extraction, restriction confirmation was performed, using 
EcoRI and BamHI. Plasmids were sequenced to confirm the presence of the desired 
mutations.  
 
Plasmids pFemA-UK, pFemA-Lys33, pFemA-Arg220 and pFemA-Tyr327 were 
electroporated into RN4220 competent cells and transformants were selected on Ery 10 µg/ml 
plates at 30ºC. Integration of the plasmids into the chromosome was performed as described 
above. Excision and allelic exchange of the femA wt gene by the mutant copy was attempted 
by three separate methods (see below). In all cases, white colonies were streaked to TSA Ery 
10 µg/ml plates to confirm excision, to lysostaphin 5 ug/ml plates to confirm resistance and to 
TSA plates at 42ºC to confirm thermosensitivity, as femA defective mutants are lysostaphin 
resistant and thermosensitive (Kusuma et al., 2007). Allelic replacement was also checked by 
PCR with primer pairs PFEMAUP3/PFEMAUP4, PFEMAKP3/PFEMAUP4, 
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PFEMARP3/PFEMAUP4, PFEMAYP3/PFEMAUP4 for the UK17, Lys33, Arg220 and 
Tyr327 mutations, respectively. Screening PCRs were done with GoTaq polymerase, 
following manufacturer’s instructions, but with annealing temperatures 2 ºC below the 
melting temperature of the primer pair, using wild-type RN4220 and the femA mutant UK17 
strains as controls.  
 
Method I – Regular methodology for excision of pMAD plasmid as described above, except 
that mutants were plated at 37ºC instead of 43ºC.  
Method II – Integrates were allowed to grow for 10, 15, 20 and 25 generations at 30ºC 
without erythromycin, before being plated on TSA at 30ºC or 37ºC. As femA defective 
mutants are reported to have a fitness defect (Kusuma et al., 2007), this method aimed to 
isolate them before they were outcompeted by wild-type excisates in the culture.   
Method III –. Integrates were allowed to grow for 10, 15, 20 and 25 generations at 30ºC 
without erythromycin, before being plated on TSA supplemented with 5 µg/ml lysostaphin at 
30ºC or 37ºC This method aimed at introducing selective pressure during excision, to isolate 
the desired mutants as soon as the second recombination event took place.  
 
 
Cell wall analysis 
 
Cell wall extract preparation 
 
  Cell wall was purified essentially as previously described (de Jonge and Tomasz, 
1993). S. aureus cells were grown for 16 h in TSB. Cultures were diluted to an OD600 of 
0.001 and allowed to grow for approximately nine generations in fresh TSB. Cultures were 
chilled in an ice-ethanol bath and then centrifuged (15,000 x g) for 10 min at 4ºC. The cells 
were resuspended in 40 ml of cold water and added to 40 ml of boiling 8% sodium dodecyl 
sulphate (SDS, Sigma). This solution was boiled for 30 min and then allowed to cool to room 
temperature (RT). The SDS-insoluble material was collected by centrifugation (17,000 x g) 
for 15 min at 20ºC. The pellet was washed five times with warm water until no more SDS 
could be detected by the Hayashi method, to check SDS presence. Hayashi method: 0.5 mL of 
the supernatant (water as control), 0.25 mL methylene blue solution (1 volume of chloroform 
per 20 volumes of 0.5% methylene blue solution, diluted 1:100 with 0.7 mM phosphate buffer 
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pH 7.2.) and 1.5 mL chloroform, were added and samples were vortexed at maximum speed 
for 60 s and were let to settle for 1 minute. If the sample is SDS free, the lower phase presents 
as clear as the control. SDS free cells were resuspended in 1 to 2 ml of water and broken with 
glass beads (Sigma-Aldrich) in a Bio101 Savant Apparatus (Thermo Electro Corporation). 
Non-broken cells and glass beads were removed by low speed centrifugation (500 x g) for 15 
min. The collected broken cells were centrifuged (17.000 x g) for 15 min at 4ºC. The pellet 
was resuspended in 2 ml of 50 mM Tris-HCl (pH= 7) with 0.05% sodium azide and MgSO4 
at final concentration of 20mM. DNase and RNase (Sigma) were added at a concentration of 
10 µg/ml and 50 µg/ml, respectively, and the mixture was incubated for 2 h at 37ºC with 
agitation. The peptidoglycan associated proteins were removed by overnight incubation at 
37ºC with 50 µg/ml of trypsin (Whorthington) in the presence of 20 mM CaCl2. The insoluble 
material was boiled again in 1% of SDS for 15 min, collected and washed with water, as 
described above, three times. The cell wall pellet was then treated with 8 mM LiCl for 15 min 
at 37ºC, collected by centrifugation (17.000 x g) for 15 min, resuspended in 100 mM EDTA 
(pH= 7) and again incubated for 15 min at 37ºC. The pellet was washed two times with water, 
resuspended in 10 ml of acetone, sonicated for 5 min and then washed again in water, 
lyophilized, and stored at 4ºC. 
 
Preparation of highly purified peptidoglycan 
 
Peptidoglycan was obtained from purified cell wall by degradation of teichoic acids 
with hydrofluoric acid. Lyophilized cell walls were resuspended in 2 ml of ice-cold 
hydrofluoric acid for 48 h at 4ºC. Peptidoglycan was recovered by centrifugation (48.000 x g) 
for 45 min at 4ºC. The pellet was washed twice with water, twice with 50mM Tris-HCl 
(pH=7) and finally again twice with water, after which samples were lyophilized. 
 
Preparation of the muropeptides. 
 
Lyophilized peptidoglycan was resuspended in 25 mM sodium phosphate buffer with 
0.05% sodium azide (pH=5.5) to a concentration of 10 mg/ml and digested with mutanolysin 
(0,135 U/µg peptidoglycan) overnight at 37ºC. The enzyme reaction was stopped by boiling 
the sample for 5 min, and insoluble materials were removed by centrifugation (15.000 x g) for 
5 min. 
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HPLC analysis of muropeptides profiles 
 
The muropepetides profile was obtained by HPLC system analysis. The digested 
peptidoglycan was injected in a Chromolith column using a 3ml linear gradient from 0.05% of 
trifluoroacetic acid (TFA) to a 0.05 % TFA buffer with 10% acetonitrile for 26 min.  
 
 
Electrophoretic analysis of proteins by SDS-PAGE 
 
Cells were grown to exponential phase (20mL) and harvested by centrifugation (3000 
x g, 4ºC). The pellet was then washed once with equal volume of PBS and resuspended in 
1/20 of the original volume in PBS with 1 mM of PMSF (Sigma). The cells were disrupted 
with approximately 800µl of glass beads in a Bio101 Savant apparatus. Glass beads were 
removed by centrifugation at 500 × g for 5 min. 10µl of supernatant were mixed with an equal 
volume of SDS-PAGE sample buffer. Samples were applied to a 10% polyacrylamide (30% 
acrylamide/bis solution, 37.5:1) protein gel. The molecular weight marker used was the SDS-
PAGE Molecular Weight Standards, low range (Biorad). The samples were run at 20mA for 
approximately 30 minutes.  
 
 
Minimum inhibitory concentration assays  
 
MICs of relevant antimicrobial compounds were determined by broth microdilution in 
sterile 96-well plates. The medium used was TSB, containing a series of two-fold dilutions of 
each compound. Cultures of S. aureus strains and mutants were added at a final density of 
5x10-5 CFU/ml to each well. Wells were reserved in each plate for sterility control (no inocula 
added) and inocula viability (no compound added). Plates were aerobically incubated at 37 C. 
Endpoints were recorded visually after 24 and 48 h. All assays were done in duplicate. 
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Fluorescence microscopy 
 
S. aureus strains were grown for 16 hours on TSB, supplemented with erythromycin 
when needed, diluted 1:1000 in the same medium without erythromycin and allowed to grow 
to mid-exponential phase (O.D = 0.7). 1 ml of culture was centrifuged for 1 min at 13500 rpm 
at RT and resuspended in 50 µl of fresh TSB. 2 µl of culture were then placed on microscope 
slides with a thin film of 1% agarose prepared in PBS. When it was relevant to inspect 
bacterial membranes, cells were incubated with either Nile Red (Invitrogen) or FM1-43 
(Invitrogen) fluorescent lipophillic dyes at 0.5-5 µg/ml for 5 minutes at room temperature 
with shaking, before being placed on the microscope slides. When it was relevant to inspect 
nucleoid shape, cells were incubated with DAPI (Invitrogen) fluorescent DNA-binding dye at 
2 µg/ml for 10 minutes at room temperature with shaking, before being placed on microscope 
slides. Fluorescence microscopy visualizations were conducted in a Zeiss Axio Observer 
microscope equipped with a Photometrics CoolSNAP HQ2 camera (Roper Scientific), using 
Metamorph software. Analysis of fluorescent images was performed using ImageJ software. 
 
 
Substrate depletion experiments  
 
To visualize protein localization after substrate depletion, S. aureus strains and 
mutants were grown to O.D 600 nm = 0.7 and incubated for 30 minutes with either 
tunicamycin or fosfomycin at 10X the corresponding MIC values. Cells were then washed 2 
times with fresh TSB and visualized on the microscope as described above.  
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Results 
 
Construction of fluorescent derivatives of FemXAB 
 
 In order to study the localization of the FemX, FemA and FemB proteins during the 
cell cycle, we constructed fluorescent derivatives of each protein and expressed them from 
their native chromosome loci in S. aureus. The FemX protein was fused either at its C-
terminal (FemX-GFP) or N-terminal (GFP-FemX) to Green Fluorescent Protein (GFP). The 
FemA and FemB proteins were fused at their C-terminus to fluorescent protein mCherry 
(FemA-mCherry) or GFP (FemB-GFP), respectively. All fusions corresponded to the only 
copy of the specific fem gene present in the genome and were placed under the control of the 
native promoter of the respective fem genes, except gfp-femX, which was put under the 
control of the xylose promoter from B. subtilis (Pinho and Errington, 2005), that is 
contitutively expressed in S. aureus. Although each protein fusion was constructed both in 
RN4220 and COL backgrounds, the characterization of the mutant derivatives of the former 
were mostly excluded from this thesis, as RN4220 is a highly mutagenized strain and only 
suitable as a cloning intermediate.  
 
 Mutants in the Fem proteins usually display growth defects (Henze et al., 1993; 
Kusuma et al., 2007; Rohrer et al., 1999), therefore we determined the growth rates of the 
strains expressing fluorescent derivatives of the Fem proteins as a measure of the functionality 
of the fusions. Figure 10 shows the growth rates of parental MSSA strain RN4220 and of the 
strains expressing fluorescent FemX derivatives constructed in this background. Strain UK17 
has a stop codon in the femA gene, therefore expressing a truncated form of FemA, which has 
no activity (Ehlert et al., 1997). This strain was included as a control to show the effect of 
lack of a Fem protein in the cell’s division rate. We could not use a femX-inactivated mutant 
as a control because FemX is an essential protein to the cell (Rohrer et al., 1999). It is 
however important to notice that UK17 has a different genetic background from COL and 
RN4220 strains and therefore the femA mutation may eventually show different phenotypes. 
RN4220 expressing a GFP-FemX fusion was shown to have a growth rate close to the 
parental RN4220 strain, with doubling times of 24 minutes for RNpFemX-N and 19 minutes 
for RN4220. The FemX-GFP fusion mutant, on the other hand, displayed slower growth than 
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the wt strain during the exponential phase (doubling time 50 minutes) than the wild-type 
strain. This suggests a growth defect of RNpFemX-C, probably because the FemX-GFP 
protein is only partially functional. 
 
 
Figure 10 – Growth curves of MSSA strain RN4220, RN4220 expressing N-terminal (RNpFemX-N) 
and C-terminal (RNpFemX-C) GFP fusions to FemX and the femA-inactivated UK17 strain.  
 
When the same GFP N- and C-terminal fusions to FemX were expressed in the 
background of MRSA strain COL, the two resulting strains had identical growth rates and 
doubling times (35 minutes), which were similar to the parental strain COL (doubling time 30 
minutes) (Figure 11). Therefore, it seems that the presence in COL of a FemX fusion which is 
not fully functional, does not significantly affect growth. 
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Figure 11 – Growth rates for parental MRSA strain COL and COL expressing N-terminal 
(COLpFemX-N) and C-terminal (COLpFemX-C) GFP fusions to FemX.  
 
 
 We have also determined the growth rates of strain COL expressing FemA-mCherry 
(doubling time 30 minutes) and FemB-GFP (doubling time 32 minutes) fusions (Figure 12), 
which we found to be identical to parental wild-type strain COL.  
 
 
Figure 12 – Growth rates for parental MRSA strain COL and COL expressing a C-terminal mCherry 
fusion to FemA (COLFemA-C) and a C-terminal GFP fusion to FemB (COLpFemB-C).  
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The FemXAB proteins were initially identified as being essential for the expression of 
high level methicillin resistance (Berger-Bächi et al., 1989; Henze et al., 1993; Tschierske et 
al., 1999). Therefore, if the fluorescent derivatives of the Fem proteins were not fully 
functional, we would expect that their expression in the COL background would cause a 
reduction in the oxacillin minimum inhibitory concentration (MIC). To further confirm the 
functionality of the fusion proteins, we proceeded to characterize the corresponding strains by 
testing resistance to four cell-wall active compounds (Table 3). Besides oxacillin, we also 
tested resistance to lysostaphin in mutants with fluorescent proteins fused to FemA, as the loss 
of activity of this protein leads to decreased amounts of muropeptides with pentaglycine 
crossbridges, thus depleting the targets of lysostaphin (vide p.10). As it was expected, both 
sensitivity to oxacillin and resistance to lysostaphin were observed in the femA-inactivated 
strain UK17. On the contrary, expression of GFP-FemX, FemA-mCherry or FemB-GFP did 
not cause a decrease in the oxacillin minimum inhibitory concentration of strain COL and 
COLFemA-C did not show increased resistance to lysostaphin, suggesting that the Fem 
proteins are functional in these strains. It is interesting to notice that the GFP C-terminal 
fusion to FemX, which resulted in a severe growth defect in the RN4220 background, caused 
a 8-fold reduction in the oxacillin MIC of COL, further confirming that this fusion is not fully 
functional. Tunicamycin and fosfomycin are cell-wall active antibiotics which were used in 
subsequent localization studies (see p.55). COLpFemX-C exhibited increased susceptibilities 
to both tunicamycin and fosfomycin, which constitutes another indication that the 
peptidoglycan structure might have been compromised in this strain. It seems that in the COL 
background, decrease of FemX activity does not affect cell growth as in the RN4220 
background but it does have an impact in resistance to cell wall active antibiotics. The N-
terminal GFP fusion to FemX, as well as FemA-mCherry and FemB-GFP caused no changes 
in the tunicamycin and fosfomycin MICs. 
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Table 3 –Minimum inhibitory concentrations of cell wall active compounds in relevant strains used in 
this study. 
 
 
Strain 
MIC (ug/ml) 
 
Oxacillin 
 
Lysostaphin 
 
Tunicamycin 
 
Fosfomycin 
     
RN4220 0.125 - 12 19.5 
RNpFemX-N 0.125 - 12 19.5 
RNpFemX-C 0.125 - 1.5 4.8 
COL 800 0.016 50 1250 
COLpFemX-N 800 - 50 1250 
COLpFemX-C 100 - 12.5 625 
COLFemA-C 800 0.016 50 1250 
COLpFemB-C 800 - 50 1250 
COL-FemAB 400 0.016 - - 
COL-FemXA 800 - - - 
UK17 (femA-) 0.19 32 - - 
 
 
 We also tested the activity/functionality of Fem proteins derivatives by analyzing the 
bacterial cell wall composition. To this end, cell wall extracts were prepared from bacterial 
cultures. Peptidoglycan was extracted, purified and digested with mutanolysin to yield a 
mixture of muropeptides, the building blocks of peptidoglycan. These muropeptides were 
resolved by high pressure liquid chromatography (HPLC). Analysis of the resulting 
chromatogram allows the identification of monomeric muropeptides, dimers, trimers, etc. 
This system does not have enough resolution to discern beyond hexamers and, as such, 
crosslinked muropeptide above this order of magnitude elute together. The amount of 
crosslinking can then be estimated by the area of the broad peak at the end of the 
chromatogram, above 100 minutes of retention time (Figure 13). To ascertain if the C-
terminal GFP fusion to FemX on the COL background was causing loss of activity of this 
protein, the muropeptide composition of peptidoglycan of this mutant was compared to wild-
type COL strain, as it is depicted in Figure 13, panel A and Figure 14. The FemX-GFP mutant 
exhibited striking changes in muropeptide composition.  
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Figure 13 – A – muropeptide profiles of wild-type strain COL (in black) compared to the COL FemX-
GFP (in red) derivative. The fusion of GFP to the C-terminus of FemX is shown to alter the cell wall 
composition significantly. Overall, a marked increase in the ratio of unsubstituted to pentaglycine-
substituted muropeptides is visible in the profile of FemX-GFP. Peaks A, B, C and D are likely to be 
unsubstituted trimers, tetramers, pentamers and hexamers, respectively. Peaks X and Y are proposed 
to be alternative unsubstituted monomers (Rohrer et al., 1999). A decrease in the amount of 
crosslinking is also observed. B - proposed chemical structures of the peak compositions in 
muropeptide chromatographic analysis, according to de Jonge and Tomasz, 1992. Muropeptides are 
numbered according to their specific retention times. In this way, for example, a NAG-NAM-
pentapeptide molecule (1) elutes first, while an octamer (21) elutes last. G= N-acetylglucosamine; M = 
N-acetylmuramic acid.  
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Figure 14 - Muropeptide profiles of wild-type strain COL (in black) compared to the COL FemX-
GFP (in red) derivative, showing a massive increase of unsubstituted monomers (peak 1) in the cell 
wall composition of this mutant, relative to the parental strain. It is also shown that, unlike COL, 
unsubstituted muropeptides are the most prevalent species in the cell wall of COL FemX-GFP. 
 
 
The same result was obtained for the FemX-GFP mutant constructed in the RN4220 
background (data not shown). The most abundant peaks in the muropeptide profile of COL 
are 5, 11, 15, 16, 17 and 18. These correspond to monomers, dimers, trimers, etc. with at least 
one fully synthesized crossbridge that is not crosslinked to other muropeptide (see Figure 13, 
panel B). This indicates that there is a pool of muropeptides in the bacterial cell wall that are 
always readily available for crosslinking. In striking contrast, the muropeptide profile of the 
FemX-GFP mutant shows a massive accumulation of unsubstituted monomers (peak 1), with 
concomitant decrease of pentaglycine-containing ones (peak 5). Accordingly, there is also an 
increase in the ratio of unsubstituted (peak 9) to pentaglycil substituted (peak 11) dimers.  
Peaks A, B, C and D, in Figure 13, panel A, are of unknown composition but could 
correspond to unsubstituted trimers, tetramers, pentamers and hexamers, respectively. 
Globally, this mutant displayed a diminished crosslinking, relative to wild-type. Peaks X and 
Y, only visible in the FemX-GFP profile, could be alternative unsubstituted monomers, with 
different amino acid compositions in the stem peptide. Interestingly, this mutant displays an 
unusual high peak 7, which may correspond to monomers substituted with one alanine. This 
could be attributed to a broader substrate specificity of FemX in this mutant.  
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Taken together, the decreased growth rate of RNpFemX-C; the decreased MICs to cell 
wall active antibiotics of COLpFemX-C and the altered muropeptide profile of this strain, 
indicate a decreased function of the FemX protein due to the C-terminal GFP fusion. 
However, the protein has to be partially functional otherwise the cell would not be viable. It is 
noteworthy that COLpFemX-C can maintain nominal growth rates with a partial functioning 
FemX protein, unlike RNpFemX-C.  
 
 The fluorescent derivatives COLpFemX-N, COLFemA-C and COLpFemB-C were 
found to have muropeptide profiles similar to wild-type COL strain, as shown in Figure 15. 
Strain COLFemA-C seemed to display a slight reduction in the amount of crosslinking, when 
compared to the control, which was likely due to less material being injected into the column.  
These results, together with the normal growth rates and antimicrobial resistance profiles, 
indicate that the fusion proteins expressed in these strains are functional and therefore can be 
used in localization studies. 
 
 
Figure 15 – Muropeptide profiles of parental strain COL (in black) and COL expressing an N-
terminal GFP fusion to FemX (brown), C-terminal GFP fusion to FemB (blue) and C-terminal 
mCherry fusion to FemA (red). All strains expressing fluorescent derivatives of the Fem proteins 
display a muropeptide profile akin to the parental strain COL. 
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Localization of the FemXAB family of proteins 
 
Staphylococcus aureus divides symmetrically by synthesizing a division septum 
midway through the cell. After the septum is complete, the daughter cells separate to undergo 
a second round of division, in which a new septum is synthesized perpendicularly to the first 
division plane (Tzagoloff and Novick, 1977). To characterize the localization of the Fem 
proteins during the cell cycle, live clonal populations derived from a single colony of the 
constructed strains expressing functional fluorescent derivatives of the Fem proteins were 
observed by fluorescence microscopy.  
 
 The localization studies of the FemX protein were done in COL and RN4220 
backgrounds expressing the N-terminal GFP fusion to FemX. Figure 16 shows the 
localization of FemX in COL during the progression of the cell cycle. For that purpose, we 
assigned cells to four stages: the initial steps of septum synthesis, the formation of a complete 
septum, splitting of the septum and separation of the daughter cells. In order to aid the 
assignment of cells to each stage, bacterial cultures were often grown in the presence of 
membrane-binding and DNA-binding dyes. FemX was found to be present mostly at the 
membrane, including the septum, although some fluorescence at the cytoplasm was also 
observed. FemX seems to accumulate at the tips of the new division site and proceed to 
accompany septum formation during division. After, division, FemX is shown to be present 
along the membrane and accumulate randomly at new membrane sites, before localizing to 
the new division septum. As the fluorescent signal for this FemX fusion was very weak, the 
localization was confirmed on the RN4220 background. RN4220 cells are larger than COL 
cells, which also makes it easier to visualize the phenotype. The localization of FemX on 
RN4220, shown in Figure 17, was found to be consistent with COL. 
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Figure 16 – Localization of the FemX protein with an N-terminal GFP fusion during the stages of the 
cell cycle in the COL background. Class A – initial steps of septum synthesis, B – formation of a 
complete septum, C – separation of the daughter cells, D – end of division. The FemX protein is 
shown to localize generally to the membrane, accumulate at the tips of the new division site and along 
the septum. After division, FemX accumulates randomly at new membrane sites. For each class (A-D), 
two examples are shown. For each example: left – phase contrast image; right – GFP image. 
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Figure 17 – Localization of the FemX protein with an N-terminal GFP fusion during the stages of the 
cell cycle in the RN4220 background. Class A –initial steps of septum synthesis, B – formation of a 
complete septum, C – separation of the daughter cells, D – end of division. The FemX protein is 
shown to localize generally to the membrane, accumulate at the tips of the new division site and along 
the septum. After division, FemX accumulates randomly at new membrane sites. For each class (A-D), 
two examples are shown. For each example: left – phase contrast image; right – GFP image. 
 
As fusing GFP to the C-terminal region of the FemX protein resulted in mutants with 
partial loss of protein activity, we wondered whether this had affected proper localization as 
well. To this end, the FemX-GFP mutants constructed in the COL and RN4220 backgrounds 
were observed under the microscope, as it is shown in Figure 18.  
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Figure 18 – Localization of the FemX protein with a C-terminal GFP fusion during the stages of the 
cell cycle in both COL and RN4220 backgrounds. Class A – septum formation; B – separation of the 
daughter cells; C –end of division. The FemX protein is shown to be localized to the cytoplasm during 
all stages of the cell cycle. For each class (A-C), one example for the COL and one for the RN4220 
background is shown. For each example: left – phase contrast image; right – GFP image.  
 
 
These mutants displayed a very low fluorescence signal. Nevertheless, the FemX 
protein localized homogeneously to the cytoplasm during all stages of the cell cycle. This 
could be due to cleavage of GFP from the FemX fusion protein by proteolytic activity. In 
order to test this hypothesis, total protein extracts from RNpFemX-C and COLpFemX-C were 
separated by SDS-PAGE and scanned with blue laser light at 395 nm, which enables the 
detection of GFP (Figure 19). 
  
45 
 
 
 
Figure 19 – Blue laser light scanning of the protein extracts from the FemX-GFP mutants after SDS-
PAGE separation. Lane 1 – COL expressing a FemX-GFP fusion; lane 2 – RN4220 expressing FemX-
GFP fusion.  
 
A band between 75 kDa and 100 kDa was observed in both backgrounds. This is 
consistent with the expected size of a FemX (~50 KDa) and GFP (~27 KDa) fusion protein, 
implying that GFP was not being cleaved by proteolitic activity. These results led us to 
believe that the GFP fusion to the C-terminal region of FemX resulted in the protein failing to 
localize correctly to the membrane and septum. This explains the loss of FemX activity 
detected on the analysis of the muropeptide profiles of these mutants and suggests that the C-
terminal region may be important for proper localization. 
 
 The localization of the FemA protein was also studied during the cell cycle, using 
COLFemA-mCherry. Figure 20 shows the localization pattern of FemA, which was found to 
be similar to FemX. However, in this case, the signal was stronger and less fluorescence was 
observed in the cytoplasm.  
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Figure 20 – Localization of the FemA protein with a C-terminal mCherry fusion in the COL 
background during the stages of the cell cycle. Class A –initial steps of septum synthesis, B – 
formation of a complete septum, C – separation of the daughter cells, D – end of division. The FemA 
protein is shown to localize generally to the membrane, accumulate at the tips of the new division site 
and along the septum. After division, FemA accumulates randomly at new membrane sites. For each 
class (A-D), two examples are shown. For each example: left – phase contrast image; right – TX red 
image. 
 
 
 
 The localization of the FemB protein was shown be similar to FemX and FemA during 
the entire cell cycle (Figure 21).  
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Figure 21 – Localization of the FemB protein with a C-terminal GFP fusion in the COL background 
during the stages of the cell cycle. Class A –initial steps of septum synthesis, B – formation of a 
complete septum, C – separation of the daughter cells, D – end of division. The FemB protein is 
shown to localize generally to the membrane, accumulate at the tips of the new division site and 
proceed along the septum. After division, FemB accumulates randomly at new membrane sites. For 
each class (A-D), two examples are shown. For each example: left – phase contrast image; right – GFP 
image. 
 
 The FemX, FemA and FemB proteins were found to localize around the entire 
membrane, including the septum, during the cell cycle. The localization at the division septum 
was expected, as that is the site of the cell where peptidoglycan synthesis occurs (Pinho and 
Errington, 2003), therefore where the Fem susbtrate (lipid II) should be localized. The 
observed permanent localization at the entire membrane was surprising. It seems that even 
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during septum formation and division there is always a pool of Fem proteins localized to the 
“lateral” membrane.  
 In order to determine if FemX, FemA and FemB are, in fact, localized over the entire 
membrane and not accumulating at the septum during division, we measured the fluorescence 
intensity signals at the lateral membrane and septum of COLpFemX-N, COLFemA-C and 
COLpFemB-C cells (n=100 for each). Wild-type COL cells (n=100) stained with lipophillic 
membrane dye Nile Red were also quantified, as a control. Only cells displaying a closed 
septum were considered. The fluorescence intensity values were normalized by subtracting 
the intensities of the background autofluorescence. The ratio of septal vs. lateral membrane 
intensity was calculated in each cell and plotted, as seen in Figure 22. Also shown are the 
values for a COL derived strain expressing an N-terminal GFP fusion to division protein 
PBP2. It has been demonstrated previously that PBP2 accumulates at the septum during 
division (Pinho and Errington, 2005). The septum is composed of two membranes, therefore 
if a fluorescent protein is equally distributed over the entire cell surface, the septal/lateral 
fluorescence ratio is expected to be close to 2. On the contrary, if a protein accumulates at the 
septum during cell division, the septal/lateral ratio is expected to be at above 2, as it was 
observed for PBP2 (average ratio - 3.97) (Figure 22). The calculated average ratios for FemX, 
FemA and FemB (1.93, 1.98 and 1.85, respectively) were found to be similar to the value 
obtained for membrane-stained cells (2.02). Therefore, it seems that Fem proteins are not 
specifically recruited to the division septum during bacterial division. 
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Figure 22 – Quantification of septum vs. lateral membrane fluorescence ratios for COLpFemX-N, 
COLFemA-C, COLpFemB-C, COLpPBP2-31 (expressing a GFP-PBP2 fusion) and COL stained with 
membrane dye Nile Red (n=100 for each strain). All cells displayed closed septa. The average ratios 
calculated for each fluorescent signal are depicted as straight lines: FemX – 1.91; FemA – 1.98; FemB 
– 1.85; PBP2 – 3.97; Membrane – 2.02. Fem proteins are shown to be evenly distributed along the 
membrane, unlike PBP2, which accumulates at the septum.  
 
To further confirm that the Fem proteins were not accumulating in the septum, we 
visualized the COLpFemX-N, COLpFemA-C and COLpFemB-C mutants on the microscope 
after incubation with DNA labeling dye DAPI. We then selected cells (n=100 for each strain) 
in the latter stages of division, where two individualized nucleoids were already discernible 
and a fully-formed septum was present. These cells were quantified as described above and 
the average ratio of septum/lateral fluorescence was found to be approximately 2 for each 
protein, confirming the even distribution of the Fem proteins over the membrane. 
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Fem proteins co-localization 
 
 After having shown that Fem proteins did not accumulate at the septum before or 
during division, we wondered whether the apparently random membrane accumulations often 
observed during the cell cycle were coincident between proteins. Therefore, we decided to 
express pairs of two fluorescent proteins in the same cell. For this purpose, mutants COL-
FemAB, expressing both FemA-mCherry and FemB-GFP fusions, and COL-FemXA, 
expressing both GFP-FemX and FemA-mCherry fusions were constructed. Table 4 
summarizes the characterization of these mutants, which were found to have doubling times, 
MICs for oxacillin and lysostaphin, and muropeptide profiles similar to the parental strain 
COL.  
 
Table 4 – Characterization of the parental MRSA strain COL and the derived COL-FemAB and COL-
FemXA strains  
 
 
Strain 
 
Doubling time (min) 
MIC (µg/ml) 
 
Cell wall 
analysis 
 
Oxacillin 
 
Lysostaphin 
COL 29 800 0.016 COL 
COL-FemAB 36 400 0.016 = COL 
COL-FemXA 35 800 0.016 = COL 
 
 
When strain COL expressing FemA-mCherry and FemB-GFP was visualized by 
fluorescence microscopy, the FemA and FemB proteins appear to co-localize during all stages 
of the cell cycle and the random accumulations of FemA and FemB seem to be coincident in 
space and time. Three stages were chosen to depict this: the initial steps of septum synthesis, 
the formation of a complete septum and the separation of the daughter cells, as shown in 
Figure 23. In all cases, cells were exposed first to the mCherry channel and then to the GFP 
channel. 
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Figure 23 – Co-localization of FemA and FemB proteins during the cell cycle in COL-FemAB strain. 
Stage A – initial steps of septum synthesis; B – formation of a complete septum; C – separation of the 
daughter cells. Each stage: phase contrast image, TX red image, GFP image. Both proteins were found 
to be present in the same subcellular structures at the same time.  
 
 
Figure 24 shows the co-localization study of GFP-FemX and FemA-mCherry proteins 
expressed in COL. Two stages of the cell cycle were chosen for this study: septum formation 
and end of division/separation. FemX and FemA were found to be co-localized during the end 
of division/separation in all cells observed and accumulating in the same distinct membrane 
spots (panel B). In contrast, during septum formation, most cells displayed protein co-
localization (64%, n= 300), while in others, FemX was present at the septum while FemA was 
accumulated at the lateral membrane (36%, n= 300) (panel A).  
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Figure 24 – Co-localization of FemX and FemA proteins during the cell cycle, as observed in the 
COL-FemXA strain. Stage A – septum formation; B – division/separation. Each stage – phase contrast 
image; TX Red contrast image; GFP contrast image. The proteins were found to co-localize during the 
end of division/separation in all cells observed. 36% of cells that displayed a division septum formed 
(n=300) were found to have FemX localized to it, while FemA was localized to distinct spots in the 
membrane. 64% of cells that displayed a division septum formed were found to have both proteins co-
localized.  
 
 In order to test the possible earlier presence of FemX at the septum compared to 
FemA, 100 cells displaying defined green fluorescence at the septum and red fluorescence 
apparently absent from it were analyzed. The fluorescence intensity signals of GFP and 
mCherry were quantified at the membrane and septum of these cells and normalized by 
subtracting the intensities of the background autofluorescence. The ratio of septal vs. lateral 
membrane fluorescence intensity was calculated in each cell for each channel and plotted, as 
seen in Figure 25. In this way, an average ratio of 1.53 was determined for green fluorescence 
(FemX), while an average of 0.74 was determined for red fluorescence (FemA). This implies 
that, at the early steps of the synthesis of the division septum, FemA is not present at the 
septum, maybe because it was actively excluded. 
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Figure 25 – Septum/membrane fluorescence ratios in 100 chosen cells of the COL strain expressing 
GFP-FemX and FemA-mCherry. These cells displayed green fluorescence at the septum and red 
fluorescence seemingly absent from it. An average 1.5 signal ratio was detected for the GFP signal, 
while an average 0.74 signal ratio was detected for mCherry. These results indicate that at this defined 
point in the cell cycle, there is localization of FemX at the septum while FemA is absent from it.  
 
 
As FemA was shown to co-localize with FemB throughout the cell cycle, to further 
test if this pair was excluded from the initial steps of septum formation, we incubated the 
COL strain expressing a C-terminal GFP fusion to FemB with FM 1-43 red membrane dye. A 
subpopulation of 300 cells displaying early septum synthesis at the division site was inspected 
on both red and green channels and FemB was found to be localized to the division site in 
every cell, thus disproving the theory of septal exclusion. Wild-type COL strain was also 
incubated with the membrane dye and visualized on both channels, to discard the possibility 
of emission on the green channel by the FM-143 fluorophore (data not shown). 
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Inactivation of the femA gene 
 
 After having determined the localization of FemX, FemA and FemB, we wanted to 
assess if interactions between these proteins were important for localization. For this, we 
attempted to inactivate the femA gene, to see if the FemB protein would de-localize in the 
absence of FemA or in the presence of a FemA protein which had lost its activity (but not its 
correct folding). As femA is encoded in the policystronic femAB operon, we opted not to 
knockout the entire gene, to avoid interfering with the mRNA transcript. Instead, we 
attempted to promote the allelic replacement of femA using the thermosensitive plasmid 
pMAD (see Methods) by a copy of the femA gene from the UK17 strain, containing a 
premature stop codon. We have also tried to substitute putative key residues of FemA by 
alanines by site-directed mutagenesis. The selected residues had been proposed to have a role 
in substrate recognition (Lysine33 and Arginine220) or in tRNA-Gly stabilization (Tyr327) 
(Biarrotte-Sorin et al., 2004; Maillard et al., 2005).  
Allellic replacement of wild-type copies of S. aureus femA by the desired mutant 
alleles proved to be unsuccessful in all attempts. The pMAD plasmid carrying the mutant 
femA allele could integrate into the chromosome by homologous recombination. However, 
this always happened through the region downstream of the mutation and therefore we never 
obtained a mutant allele under the control of the native promoter. Furthermore, excision of the 
plasmid from the chromosome always generated wild-type strains and never strains 
containing the desired mutations. Figure 26 shows the attempted replacement of wild-type 
femA by the UK17 allele, as an example.   
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Figure 26 – Strategy for allellic replacement of the wild-type femA gene in RN4220 by the femA allele 
from the UK17 strain, cloned into the pMAD plasmid. This allele contains a point mutation (depicted 
by an asterisk) leading to a premature stop codon and subsequent expression of a truncated FemA 
protein. Integration through homologous recombination always occurred downstream of the point 
mutation, despite the upstream region having the same length. The second recombination event and 
loss of the plasmid always yielded wild-type colonies. Step 1 – homologous recombination between 
pFemA-UK and the bacterial chromosome; step 2 – integration (blue colonies); step 3 – second 
recombination event and loss of the plasmid (white colonies). Flag – native promoter of the femAB 
operon.  
 
We modified the protocol for allelic replacement in several ways in order to maximize 
chances of isolating mutants: 
 
i)  femA-inactivated strains like UK17 were shown to be thermosensitive (Kusuma et al., 
2007). Therefore, during excision, we kept the final temperature at a maximum of 
37ºC instead of 43ºC (see methods), to avoid losing the desired mutant. After the 
excision, we obtained the expected 1-5% of white colonies for double cross-over 
event. Screening PCR was performed on 20 clones for each of the four desired 
mutations and it was found that all carried wild-type copies of femA.  
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ii) As the doubling time of UK17 is twice as long as RN4220, it could be expected that 
growth of mutants carrying an inactivated femA locus would quickly be overtaken 
by wild-type cells. To try to avoid this, the excision protocol was modified. 
Colonies with integrated pMAD plasmid carrying the femA mutant alleles were 
allowed to grow for only 10 generations, instead of 30 (see Methods) at the 
permissive temperature before being plated. This process aimed to provide enough 
time to ensure that the second recombination event would likely occur, but trying 
to circumvent the expected fitness deficit of femA mutants, by plating earlier. With 
10 generations only, the number of white colonies obtained was only 1%. Again, 
20 excisates for each mutation were screened and none found to contain the 
desired replacements. 
 
iii)  As femA mutants are lysostaphin resistant, we also tried to introduce a final plating 
step in a lysostaphin 5 µg/ml plate, to select only the allelic replacement mutants 
and inhibit growth of wild-type cells. Colonies grew on lysostaphin plate but none 
of them carried the desired mutations in the femA gene and were proposed to be 
spontaneous mutants.  
 
Despite the repeated attempts and different modifications of the protocol, inactivation of 
femA was always unsuccessful. These results suggest that femA may well be a lethal target 
and that the only reason that UK17 can cope with lack of FemA activity is by having 
compensatory mutations elsewhere in the chromosome. 
 
 
Substrate dependency of the FemXAB family of proteins for localization 
 
 In order to assess if the localization of FemX, FemA and FemB proteins was 
dependent on interactions with the substrate, similarly to what happens for PBP2 (Pinho and 
Errington, 2005), we treated bacterial cultures of COL GFP-FemX, COL FemA-mCherry and 
COL FemB-GFP mutants with either tunicamycin or fosfomycin. Tunicamycin is a potent 
inhibitor of the MraY translocase (Lin et al., 2002), thus preventing the peptidoglycan 
cytoplasmatic precursors from being attached to the lipid carrier bactoprenol. Fosfomycin 
inhibits the MurA enzyme, which catalyzes the first step commited to peptidoglycan 
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biosynthesis, therefore blocking peptidoglycan synthesis at the initial step in the cytoplasm 
(Kim et al., 1996). Cells were incubated for 30 minutes with 10 times the determined MICs 
for each antibiotic and each strain, before being visualized under the microscope. Figures 27-
29 depict the effect of these compounds on the localization of FemX, FemA and FemB, 
respectively. Cells appeared more aggregated and smaller/larger, when compared to untreated 
cells. These variations in cell size seem to be random in the studied populations. Localization 
of the three proteins on the lateral membrane and septa was lost. FemXAB proteins were 
shown to delocalize randomly across the cell, forming patches or dense accumulations. There 
was no observed difference between the treatment with fosfomycin and tunicamycin. These 
results suggest that the presence of the substrate is required, directly or indirectly, to keep 
FemX, FemA and FemB in place.  
 
 
Figure 27 – Delocalization of FemX in COL GFP-FemX strain after treatment with cell-wall active 
compounds at 10X the corresponding MIC values for 30 minutes. Membrane and septum localization 
of FemX is lost, with the protein accumulating randomly throughout the cell. A – with fosfomycin; B- 
with tunicamycin; C – control, no compounds added. For each panel, left – phase contrast image; right 
– GFP image 
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Figure 28 – Delocalization of FemA in COL FemA-mCherry strain after treatment with cell-wall 
active compounds at 10X the corresponding MIC values for 30 minutes. Membrane and septum 
localization of FemX is lost, with the protein accumulating randomly throughout the cell. A – with 
fosfomycin; B – with tunicamycin; C – control, no compounds added. For each panel, left – phase 
contrast image; right – TX red image. 
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Figure 29 – Delocalization of FemB in COL FemB-GFP mutant after treatment with cell-wall active 
compounds at 10X the corresponding MIC values for 30 minutes. Membrane and septum localization 
of FemB is lost, with the protein accumulating randomly throughout the cell. A – with fosfomycin; B 
– with tunicamycin; C – control, no compounds added. For each panel, left – phase contrast image; 
right – GFP image. 
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Discussion 
 
 The unique FemXAB family of non-rybosomal peptidyl transferases catalyzes the 
stepwise addition of glycine residues to the stem peptides of the peptidoglycan precursors. 
FemX adds the first glycine, FemA adds the second and the third, FemB adds the fourth and 
the fifth. Our study of the localization of FemXAB proteins began by constructing a C-
terminal GFP fusion to FemX on both MSSA and MRSA backgrounds. The protein appeared 
in the cytoplasm of the cell during growth and division, with no specific subcellular 
localization detected. Characterization of the cell wall composition and antibiotic resistance 
profile of these mutants revealed significant differences to the wild-type parental strains, 
leading us to conclude that FemX’s function was partially hindered as a result of the GFP 
fusion to its C-terminus region. As FemX is an essential protein, it was interesting to analyze 
the consequences to the cell of having a partial loss of function of this protein. The most 
striking feature of FemX-GFP muropeptide profiles was the massive accumulation of 
muropeptide monomers with no glycine crossbridges, as opposed to muropeptides with a 
complete crossbridge present in wild-type strains. Similarly, there was accumulation of 
dimers with one pentaglycine crossbridge, trimers with two pentaglycine crossbridges, etc.  
In wild-type strains, muropeptides with pentaglycine side chains, the substrates for the 
crosslinking reactions, are abundant in the peptidoglycan, suggesting that this pool of 
muropeptides is permanently available to the PBPs and, therefore, that the activity of the Fem 
proteins does not constitute a bottleneck in PG biosynthesis. The presence of the partially 
functional FemX results in a lower pool of crosslinkable muropeptides, as it is postulated that 
PBPs cannot crosslink unsubstituted muropeptides (de Jonge et al., 1993). In these conditions, 
the FemX activity may be limiting for efficient PG biosynthesis. Another interesting feature 
of these FemX mutants is the accumulation of muropeptides with an alanine at the first 
position of the crossbridge, that are virtually absent from wild-type strain profiles. 
Muropeptides with serines or alanines in the crossbridge have been previously reported in 
femA mutant strains (de Jonge et al., 1993; Strandén et al., 1997) and in wild-type strains 
grown in a glycine poor medium (Swenson and Neuhaus, 1976). This suggests the presence of 
a FemX-like transferase protein present in S. aureus that is able to add alanine residues. 
Homologues of the MurM protein of S. pneumoniae are likely candidates for this function. 
This protein initiates the synthesis of the crossbridge in these species and it was shown to be 
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specific for either alanine or serine charged tRNA binding, depending on allele variability of 
the murM gene (Filipe et al., 2001; Filipe and Tomasz, 2000). It is unlikely that this activity 
results from FemA or FemB, as their substrate specificities are thoroughly described 
(Schneider et al., 2004). In wild-type strains, both FemX and the alanyl transferase could 
compete for the muropeptide substrate, with the former being able to bind it more efficiently. 
This would explain why, in the presence of a partially functional FemX protein, alanine 
containing muropeptides would accumulate in the cell wall. Alternatively, it is possible that 
the C-terminal fusion of GFP to FemX would decrease its specificity to glycine charged 
tRNAs by some extent. In the aforementioned MurM, a 30 amino acid segment contained in 
the coiled-coil helical arms of the protein was determined to be critical for the selectivity of 
tRNA recognition (Filipe et al., 2001). This segment seems to be, however, structurally 
distant from the C-terminal domain of MurM (Fiser et al., 2003). The muropeptide binding 
domain of Fem and Fem-like proteins is at the vicinity of the C-terminus of the protein, 
however C-terminal fluorescent protein fusions to FemA and FemB constructed in this work 
did not affect these proteins’ activities or localization. It is therefore unlikely that the fusion 
disrupted the specificity of FemX to glycil-tRNA or its proper muropeptide recognition.   
Muropeptides containing an alanine seem to be poor substrates for FemA as they 
accumulate massively in the FemX mutant. On the contrary, monoglycil substituted 
muropeptides are never accumulated. Muropeptides containing one alanine and 2-4 glycines 
in the crossbridge are also not present in the peptidoglycan composition of the FemX mutant, 
further confirming the substrate specificity of FemA for monoglycil substituted precursors. 
Given the changes in PG precursors’ availability and, by extension, the amount of PG 
crosslinking, it could be expected that expression of a not fully functional copy would cause 
severe growth defects in the bacteria. This was found to be true in the MSSA strain RN4220, 
but not in MRSA strain COL. Strain RNpFemX-C had a 2,5-fold increase in doubling time 
and a longer lag phase, comparatively to wild-type. The growth rate of COLpFemX-C, on the 
other hand, is only slightly reduced, compared to wt COL. This suggests that in the COL 
background, despite the reduced FemX activity, there is a sufficient muropepeptide precursor 
pool to maintain normal growth. The COL strain takes on average 10 minutes more than 
RN4220 to divide, therefore different metabolic flux, namely for PG biosynthesis, may be 
characteristic of this strain. This would explain the ability of COL to maintain growth rate 
without a fully functional FemX protein. However, it is important to notice that, despite the 
normal growth, a reduction in FemX activity caused an increased susceptibility to cell wall 
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active compounds in strain COL, similarly to what was observed for RN4220. This is in 
accordance to previous data that implicate FemXAB proteins in oxacillin resistance (Strandén 
et al., 1997). As the localization of FemX with a C-terminal GFP fusion was shown to be 
mainly cytoplasmic, we believe that the C-terminus of FemX may be a critical region for 
protein-protein or protein/substrate interactions responsible for keeping this protein at the 
membrane, where it is active. 
 
N-terminal GFP fusion to FemX in COL and RN4220, as well as C-terminal GFP or 
mCherry fusions to FemA and FemB, yielded mutants with wild-type cell wall muropeptide 
composition and similar growth rates to the parental strains. The oxacillin MIC of COL 
expressing fluorescent derivatives of the FemXAB proteins was also identical to the one of 
parental strain COL. As functional FemXAB proteins are essential for the expression of β-
lactam resistance in COL, this result is a further indication that the fusions are functional and 
can be used for localization studies.  
When the localization of FemX was studied in live S. aureus cells, the protein was 
found to be at the membrane and to accumulate around the future division site, corresponding 
to spots on the microscopy images. FemX then accompanied the closing of the septum, 
although it did not localize exclusively at the septum, but rather over the entire cell 
membrane. At the end of division, when the daughter cells are ready to separate, FemX 
localized over the entire membrane of both daughter cells, accumulating randomly in spots 
during separation and before the next round of division. FemA and FemB proteins were found 
to have a pattern of localization akin to FemX during the cell cycle.  
The membrane localization of the FemXAB family was unexpected because these 
proteins lack a transmembranar domain or membrane anchors. As protein-protein interactions 
between FemA and FemB proteins have been described previously (Rohrer and Berger-Bächi, 
2003), we wondered whether proper localization and activity of the FemA protein was vital 
for FemB also to localize and, therefore, we sought to express FemA proteins either truncated 
or with loss of activity in S. aureus. Our attempts at inactivating femA during this work 
proved to be fruitless. Despite successive attempts to replace the wild-type allele by a mutated 
femA, it was never possible to obtain the desired mutants, even when using lysostaphin, to 
which femA mutants are resistant, as a selection. Therefore, we were not yet able to study if 
FemB is dependent of FemA for proper localization. Since the discovery of the femAB 
operon, there have been numerous attempts to inactivate the femA gene, using a variety of 
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methods. In one experiment to address this issue, a femAB null mutant (AS145) was 
constructed by replacing the operon with a tetracycline resistance cassette (Tet), followed by 
screening of positives in lysostaphin plates (Strandén et al., 1997). This mutant was shown to 
have exclusively monoglycine crossbridges in its peptidoglycan, severe growth defects and 
hypersusceptibility to β-lactams. Complementation with either intact femA or femAB copies 
resulted in the extension of the crossbridges to triglycines and pentaglycines, respectively. 
Surprisingly, complementation in these mutants did not restore normal growth rate nor β-
lactam resistance as was expected. Furthermore, transduction of the Tet resistance marker to 
other strains was always unsuccessful, except when lysostaphin was added as a second 
selective agent. In another experiment, by means of chemical mutagenesis with ethyl 
methanesulfate upon MRSA strain BB270 and subsequent selection on lysostaphin plates, 
mutants UK14-20 were isolated. Sequencing of the femA gene in these mutants revealed point 
mutations expected by the treatment with the mutagenic agent, along with spontaneous 
mutations selected for by growth on lysostaphin, both leading to the expression of truncated 
FemA proteins (Ehlert et al., 1997). Spontaneous mutants obtained after selective pressure on 
lysostaphin have also been reported recently, both in vitro and during preclinical trials of 
lysostaphin therapy for S. aureus infections. These isolates, like the UK strains, were shown 
to have mutations in the femA genes, a femA-like phenotype and also decreased virulence 
(Kusuma et al., 2007). Taken together, these results indicate that femAB deletion by itself may 
be lethal unless some compensatory mutation occurs to allow survival. The existing femAB 
null mutant (AS145) and the femA point mutants (UK) probably have metabolic changes that 
allow them to grow with such drastically reduced side-chains (Ling and Berger-Bächi, 1998). 
It is interesting to mention that three of the four femA mutant alleles that we were trying to 
introduce in the S. aureus chromosome contained mutations in residues which are only 
postulated to be important for the activity of FemA (Lys33, Arg220, Tyr327). The fact that 
these mutations were never found during the allelic replacement PCR screenings, suggested a 
determining role in the activity of FemA. The successful replacement of the wild-type femA 
allele by a femA-mCherry allele that was performed for the localization studies validates the 
methodology employed in cloning mutated femA constructs.  
 
The observed pattern of localization of FemXAB proteins is in contrast to the pattern 
of the cell wall synthethic enzymes that have been previously studied in S. aureus, namely 
PBP1 and PBP2. These proteins were shown to localize specifically at the septum (Pereira et 
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al., 2007; Pinho and Errington, 2005). Fem proteins, on the other hand, were shown here not 
to accumulate in the division septum, which suggests that this protein family does not 
necessarily function exclusively at the septum. PBP2, like all high molecular weight PBPs, 
contains an N-terminal non-cleavable signal peptide that is anchored to the cytoplasmic 
membrane and accumulates at the septum, the main place where cell wall synthesis occurs. 
Substrate recognition is crucial for the protein’s localization, as PBP2 was shown to become 
dispersed over the entire cell surface after being acylated by oxacillin (Pinho and Errington, 
2005). All three Fem proteins were shown here to accumulate randomly in patches throughout 
the cell when it was challenged with cell-wall active antibiotics tunicamycin and fosfomycin, 
which resulted in the inhibition of the synthesis of the substrate of FemX. This suggests that 
Fem proteins are dependent on their membrane-bound substrates for proper localization and, 
as they do not possess an anchor that would hold them at the membrane after substrate 
depletion, they are released into the cytoplasm. Alternatively, as the tested compounds are 
likely to affect all reactions downstream of the reactions they inhibit, their addition could 
result in loss of protein-protein interactions, which could be responsible for keeping the Fem 
proteins at the membrane.  
  
 Fem A and FemB proteins were found to co-localize during all stages of the cell cycle, 
which is in agreement with the hypothesis, although not proving it, that these proteins 
function together, maybe as heterodimers or even tetramers of two subunits of each (Rohrer 
and Berger-Bächi, 2003). FemX was shown to co-localize with FemA in most of the cells 
displaying septa, but a subpopulation in which FemX localized to the division site before 
FemA was also observed. This is in accordance with the biochemical activity of each protein: 
FemX is essential and adds the first glycine and therefore its activity drives the whole 
crossbridge formation event and it is reasonable to assume that it localizes first to the 
substrate. However, it still is curious that there was a time gap between the FemX and the 
FemA reactions so perceptible that it actually could be detected in nearly 40% of the cells 
preparing to divide. It was shown by Schneider and colleagues (Schneider et al., 2004), that 
FemA and FemB interfered with the FemX reaction in vitro, probably because both these 
proteins recognize the phosphate moieties of lipid II and compete for them. FemX was shown 
to add the first glycine to lipid II in vitro within 5 minutes, when incubated in the absence of 
FemA and FemB. When FemA or FemAB were added to the reaction, the incorporation of the 
first glycine was delayed to 15 minutes and 30 minutes, respectively. It is, therefore, 
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reasonable to assume that the cell could have mechanisms to prevent FemA (and FemB) to 
localize to the division septum when FemX is adding the first glycine residue. Although this 
preposition is theoretically logical, it was not validated by membrane staining of bacteria 
expressing FemB-GFP, as septal exclusion of FemB was not verified in any cells.  
 
We propose a model for FemXAB localization in which molecules of the lipid II 
precursor of peptidoglycan are present over the entire membrane during the cell cycle. This 
implies that the first membrane-bound stages of the peptidoglycan biosynthesis also occur 
outside of the septum. The FemXAB proteins would localize to the membrane either by 
substrate interactions via recognition of the sugar moieties of lipid II, by protein-protein 
interactions or by both, and synthesize the pentaglycin-substituted lipid II, which becomes 
evenly distributed along the membrane, including the septum, where it is presumably 
translocated to the outer membrane. The transpeptidation/transglycosilation machinery of the 
bacterium is also accumulated specifically in the septum, ensuring that lateral growth is kept 
to a minimum.  
Alternatively, the Fem proteins could localize to the membrane via structural motifs. 
S. aureus FemA possesses a coiled-coil domain. By analogy of sequence similarity, FemB 
and FemX, whose structures are still unresolved, should also comprise this domain. Coiled-
coil motifs have been found to be essential for proteins localized to membranes, or interacting 
with membrane proteins, such as Caulobacter Crescentus Crescentin (Margolin, 2004) or 
Bacillus subtillis DivIVA (Lenarcic et al., 2009). Interestingly, the FemX protein of W. 
veridescens does not possess this coiled-coil domain and its activity has been thoroughly 
described to lie in the cytoplasm (Biarrotte-Sorin et al., 2004; Maillard et al., 2005). The 
FemXAB family in S. aureus could be present at the membrane and recognize the lipid II 
substrate. However, the FemA and FemB proteins may compete with FemX for the substrate, 
inhibiting the FemX reaction at the lateral membrane and therefore preventing theaddition of 
any glycines to lipid II. During the early stages of the septum formation, FemX would interact 
weakly with an initial division protein, such as FtsZ, for example, possibly via its C-terminal 
region. FemA and FemB may not be able to interact with these complexes and would not be 
recruited to the septum. FemX would start adding the first glycine to the lipid II present at the 
septum, generating the substrate of FemAB. Finally, FemA and FemB would then also 
accumulate to the tips of the division septum, perhaps by interactions with the substrate or 
with the hypothethical flippase. As this machinery moves on, FemA and FemB add the 4 
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glycines to lipid II-Gly1 successively as a putative tetramer that could then be translocated, 
transglycosilated and transpeptidated into the growing glycan chain, thickening the septum.  
Further studies into possible interactions between Fem proteins among themselves and 
with other division proteins will hopefully allow us to shed further knowledge into the 
complexities of bacterial peptidoglycan synthesis.  
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